[{"text": "What Are Analysts Talking About Cytokinetics (CYTK)? Jabran Kundi Tue, Jan 28, 2025, 12:50 AM 3 min read In This Article: CYTK -2.01% We recently published a list of 10 Stocks That Analysts Are Talking About . In this article, we are going to take a look at where Cytokinetics, Incorporated (NASDAQ:CYTK) stands against other stocks that analysts are talking about. Like any other informed investor, we are always on the hunt for stocks that analysts are talking about. Analysts use their in-depth research expertise, industry knowledge, and industry connections to figure out how well companies are doing every quarter. Once they stumble upon something that could change the course of that company\u2019s stock, they come out with analyst updates. These are usually in the form of an upgrade or downgrade, or simply an update on a previously assigned rating. For retail investors, going through these reports saves a lot of time. This is why we came up with 10 stocks that analysts are talking about this week. To come up with the list of 10 stocks that analysts are talking about, we considered companies that received an analyst upgrade or coverage in the last 5 days. Are Analysts Talking About Cytokinetics Incorporated (CYTK)? A lab technician using a microscope to examine the biopharmaceutical company's molecules. Cytokinetics, Incorporated (NASDAQ:CYTK) Cytokinetics, Incorporated (NASDAQ:CYTK) is a late-stage pharmaceutical company committed to developing, commercializing, and discovering inhibitors and muscle activators. The financial research firm Stifel started analyst coverage of CYTK with a Buy rating due to its new promising drug, aficamten, promising an exciting couple of years ahead. According to Stifel, aficamten is an extraordinary drug with a high competitive bar. Even outside the US, the drug is set to bring in millions of dollars of revenue for the company. In December, one of the company\u2019s partners transferred the rights for the drug in China, Taiwan, and Hong Kong to Sanofi. Cytokinetics (NASDAQ:CYTK) is set to receive $150 million in a one-time payment and somewhere between $10-$20 million in sales. In Japan, the company has struck a similar deal with Bayer. In this way, Cytokinetics (NASDAQ:CYTK)can now focus on marketing the drug in the US while leaving its international operations to companies that have a better global presence. The stock is down 43% in the last year, though that has a lot to do with Novartis walking away from an M&A deal. Apart from the promise of aficamten, new M&A activity cannot be ruled out and forms one of the components of Stifel\u2019s bullish thesis on the stock. Overall, CYTK ranks 10th on our list of stocks that analysts are talking about. While we acknowledge the potential of CYTK as a leading AI investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is as promising as CYTK but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock . Story Continues READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap Disclosure: None. This article is originally published at Insider Monkey . View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CYTK", "date": "2025-01-28T00:50:38", "sentiment": {"score": 0.1460300013422966, "confidence": 0.15797802805900574, "probabilities": {"positive": 0.15797802805900574, "negative": 0.011948026716709137, "neutral": 0.8300739526748657}}, "embedding": [-0.13155172765254974, -0.07831592857837677, -0.04959690198302269, -0.05133461579680443, -0.014091912657022476, 0.01422511413693428, 0.049555689096450806, 0.27374035120010376, 0.1349761039018631, 0.05108002573251724, -0.09728871285915375, 0.07591774314641953, 0.07507208734750748, 0.029711853712797165, -0.12842805683612823, 0.021483656018972397, 0.09393319487571716, 0.12859569489955902, -0.10202844440937042, -0.020202547311782837, -0.16930736601352692, -0.08312959969043732, 0.08390579372644424, 0.025462143123149872, 0.0585859939455986, 0.019818846136331558, -0.07095810770988464, -0.05147567763924599, -0.2047576606273651, 0.06575863808393478, -0.08945836126804352, 0.18720073997974396, 0.1415417641401291, 0.0197991244494915, -0.06121106445789337, 0.024926181882619858, -0.11783833801746368, 0.06387938559055328, 0.04639647901058197, 0.0232484620064497, 0.035048216581344604, 0.0016079312190413475, -0.12045326828956604, 0.06940877437591553, 0.08509582281112671, -0.026220383122563362, 0.028510339558124542, 0.009912588633596897, -0.010407526046037674, 0.016665440052747726, -0.1852957010269165, -0.14143119752407074, 0.047136057168245316, 0.06180447340011597, -0.061407677829265594, -0.005692627746611834, -0.2445085644721985, -0.003812869545072317, 0.06826625764369965, 0.04191601276397705, 0.029200777411460876, 0.024449415504932404, 0.057729918509721756, 0.07150176167488098, 0.1527823507785797, -0.003441559849306941, -0.07523252069950104, 0.10580375045537949, 0.021321671083569527, -0.0563165619969368, 0.033945247530937195, -0.10127099603414536, -0.06210974603891373, 0.09014441072940826, -0.17319734394550323, 0.13559851050376892, 0.14200221002101898, 0.12434697151184082, 0.0736510381102562, -0.16805410385131836, 0.1275569200515747, -0.0371674969792366, 0.12125587463378906, -0.061134856194257736, -0.05299212038516998, -0.04851735383272171, 0.014145726338028908, 0.14523887634277344, 0.022898489609360695, 0.11230279505252838, 0.10544247925281525, 0.047805555164813995, 0.03882565721869469, -0.043438997119665146, -0.0029155798256397247, -0.03531841188669205, -0.08623038977384567, 0.04727082699537277, 0.036073967814445496, 0.07710219919681549, 0.06070827692747116, 0.06680427491664886, 0.0012027602642774582, -0.030224034562706947, -0.15836599469184875, -0.20321115851402283, 0.0391998365521431, -0.08871980756521225, 0.08591820299625397, 0.06284715235233307, -0.13454905152320862, 0.026676911860704422, -0.1902480572462082, -0.056734271347522736, -0.08027424663305283, 0.20042452216148376, 0.023525530472397804, 0.055809058248996735, 0.13210433721542358, 0.047186464071273804, 0.08398336917161942, -0.04594258591532707, -0.006461838260293007, -0.0768282413482666, 0.024422768503427505, 0.18852022290229797, -0.21601562201976776, 7.627997370204849e-33, -0.09721632301807404, 0.03952312842011452, 0.11697667837142944, 0.027388088405132294, -0.15050610899925232, -0.031215505674481392, 0.09501439332962036, -0.07570339739322662, 0.0047986991703510284, -0.11215537786483765, -0.11982974410057068, 0.1480773687362671, -0.017066355794668198, 0.029905827715992928, -0.02195294015109539, -0.05298679322004318, -0.14013805985450745, 0.013077013194561005, -0.005541060585528612, -0.0901193767786026, 0.03623905032873154, 0.028568925336003304, -0.09353634715080261, 0.0490371473133564, -0.050019025802612305, -0.08334324508905411, -0.02025061845779419, 0.014083633199334145, -0.03684080019593239, 0.044177647680044174, -0.11452740430831909, 0.036939527839422226, -0.004727987572550774, -0.029203670099377632, -0.007112053222954273, -0.08096277713775635, -0.03314259648323059, -0.17163580656051636, 0.11768291890621185, -0.03239654749631882, -0.16262884438037872, -0.12295427918434143, -0.0744888037443161, -0.07887326180934906, 0.06611369550228119, 0.03382062911987305, -0.2750003933906555, -0.0500970296561718, -0.0502033606171608, -0.03264772891998291, 0.0051645999774336815, 0.05472015589475632, 0.007115826476365328, -0.05722074955701828, 0.021060561761260033, 0.14684107899665833, -0.04563130438327789, -0.13829654455184937, -0.017609890550374985, 0.0937047153711319, -0.03601555526256561, 0.0703551396727562, -0.058069273829460144, 0.059487003833055496, -0.1231188029050827, 0.21602463722229004, -0.14675691723823547, 0.02628181502223015, -0.1357574313879013, 0.2292184978723526, 0.004975436255335808, -0.030646830797195435, 0.1593591570854187, -0.02919573336839676, 0.12434285879135132, -0.03252386301755905, -0.09292814135551453, 0.14856429398059845, -0.0880051851272583, 0.04138369858264923, 0.07662522047758102, -0.08143243938684464, -0.07108793407678604, 0.023411404341459274, 0.03169437497854233, -0.087538942694664, 0.020529281347990036, 0.013343972153961658, -0.04644398391246796, -0.023850079625844955, 0.07389210164546967, -0.07181128859519958, -0.11421692371368408, 0.21956875920295715, -0.028704114258289337, -8.902339040987782e-33, -0.10894756764173508, 0.04726845398545265, -0.08276300877332687, -0.020916268229484558, -0.018696635961532593, 0.028744522482156754, 0.045588161796331406, -0.049792006611824036, 0.0826592892408371, -0.04974950850009918, -0.03531219810247421, -0.026288561522960663, -0.07429231703281403, 0.04101463779807091, -0.1499989628791809, 0.018553150817751884, 0.02583710476756096, -0.030213359743356705, -0.12076748162508011, 0.02251073718070984, 0.0504031777381897, 0.02201138064265251, -0.05228827893733978, 0.08316096663475037, 0.07310198247432709, 0.07177771627902985, 0.039166465401649475, 0.121905118227005, 0.036295581609010696, 0.008531888946890831, -0.10860571265220642, -0.01045336201786995, -0.13499759137630463, 0.056468263268470764, 0.07651366293430328, 0.011115510016679764, 0.03047298640012741, -0.22349193692207336, -0.0019329283386468887, -0.06814226508140564, 0.0044596134684979916, -0.09378276020288467, 0.010141415521502495, 0.04712437838315964, 0.07969525456428528, 0.07356539368629456, 0.08092588186264038, -0.0054930755868554115, 0.10359899699687958, 0.01826321892440319, 0.05717288702726364, 0.12388505786657333, 0.09808829426765442, 0.11480690538883209, -0.15112903714179993, 0.09510832279920578, 0.06251539289951324, 0.03441493213176727, -0.020216066390275955, 0.031203290447592735, 0.0915345549583435, -0.008685294538736343, 0.07026846706867218, 0.022065313532948494, -0.0014582611620426178, -0.013875845819711685, 0.10871396958827972, 0.09510762989521027, 0.02676713839173317, -0.05070515722036362, 0.0578477680683136, -0.08131582289934158, 0.027716241776943207, -0.09220965206623077, -0.009021937847137451, 0.12518006563186646, -0.005326629616320133, -0.14902612566947937, -0.155252605676651, -0.025016291067004204, 0.02115851826965809, -0.025526495650410652, 0.07323767989873886, 0.039388224482536316, 0.010784728452563286, -0.04170466214418411, 0.029872272163629532, 0.09021280705928802, 0.011974268592894077, -0.06293828040361404, -0.018619995564222336, -0.14221185445785522, -0.11729881912469864, 0.1302044540643692, 0.036936987191438675, -1.0042429465784153e-07, 0.06046072021126747, -0.1104162186384201, -0.027257706969976425, -0.10727973282337189, 0.19472602009773254, -0.1469893455505371, -0.08426012098789215, 0.016915950924158096, 0.03333207219839096, 0.08179878443479538, 0.08266354352235794, 0.11668495833873749, -0.15525448322296143, 0.044196173548698425, -0.0041422294452786446, 0.0039166659116744995, -0.10072925686836243, 0.0006441730074584484, -0.006268897093832493, 0.047301944345235825, -0.020990723744034767, 0.07327333837747574, 0.003757212311029434, -0.026831358671188354, 0.03859291970729828, -0.09198078513145447, -0.07745606452226639, 0.0617775022983551, 0.030703432857990265, -0.012894339859485626, 0.02661941945552826, 0.04227849841117859, 0.09313813596963882, 0.049342140555381775, -0.1356762796640396, 0.006719037890434265, 0.04889136925339699, -0.011316562071442604, 0.003672072198241949, 0.06336130946874619, -0.1834416687488556, -0.1005159318447113, 0.007437040098011494, 0.05628824234008789, -0.044737376272678375, -0.07690903544425964, -0.129482701420784, 0.01551549881696701, 0.12642985582351685, -0.15624189376831055, 0.00469829561188817, 0.013416018337011337, -0.04926586151123047, -0.04665295407176018, 0.01493777334690094, 0.07440818846225739, -0.07510567456483841, -0.06349129974842072, -0.07898148894309998, -0.07595989108085632, -0.0707327276468277, -0.1814827024936676, 0.1718810498714447, 0.18284495174884796], "changes": {"1wk": -2.9435271254085964}}, {"text": "CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study Zacks Equity Research Thu, Jan 23, 2025, 7:19 PM 4 min read In This Article: CYTK -2.01% Shares of Cytokinetics CYTK gained 2.2% on Wednesday after the company began enrolling patients in its mid-stage study of CK-4021586 (CK-586), a cardiac myosin inhibitor, for treating heart failure patients. The intended patient population includes those with symptomatic heart failure with preserved ejection fraction (HFpEF) with left ventricular ejection fraction (LVEF) \u226560%. The primary goal of the phase II AMBER-HFpEF study is to evaluate the safety and tolerability profile of CK-586 compared to placebo in HFpEF patients. As secondary objectives, the study will also assess the effect of CK-586 on LVEF and NT-proBNP, and determine the candidate\u2019s pharmacokinetics\u00a0and pharmacokinetic/pharmacodynamic relationship. Other exploratory endpoints of the study include evaluating the effect of CK-586 on patient function, symptoms and measures of cardiac function. Cytokinetics plans to enroll approximately 60 HFpEF patients in the phase II AMBER-HFpEF study who will receive CK-586 or placebo in three dose escalation cohorts. In the past three months, CYTK shares have lost 10.6% compared with the industry\u2019s 8.7% decline. Zacks Investment Research Image Source: Zacks Investment Research CYTK\u2019s Other Pipeline Developmental Programs Cytokinetics is developing its lead investigational candidate, aficamten, a novel, oral and small-molecule cardiac myosin inhibitor, to reduce the hypercontractility associated with\u00a0hypertrophic cardiomyopathy (HCM). A regulatory filing for aficamten to treat obstructive HCM is currently under review by the FDA. A final decision from the regulatory body is expected on Sept. 26, 2025. The FDA also informed the company that it is not planning to hold an advisory committee meeting to discuss the application. Similar regulatory filings seeking approval for aficamten to treat obstructive HCM are also currently under review in other geographies, including the EU. Cytokinetics is also evaluating aficamten monotherapy in its phase III MAPLE-HCM study compared to metoprolol monotherapy in patients with obstructive HCM (enrollment completed) and ACACIA-HCM, a phase III study of aficamten in patients with non-obstructive HCM (enrolment ongoing). Other studies include CEDAR-HCM, a clinical study of aficamten in a pediatric population with obstructive HCM. Enrollment is ongoing in CEDAR-HCM. Another pipeline candidate is omecamtiv mecarbil, a cardiac muscle activator, which is being developed for patients with heart failure. Last month, Cytokinetics initiated COMET-HF, a confirmatory phase III study to assess the efficacy and safety of the candidate in patients with symptomatic heart failure with severely reduced ejection fraction. Story Continues Cytokinetics, Incorporated Price and Consensus Cytokinetics, Incorporated Price and Consensus Cytokinetics, Incorporated price-consensus-chart | Cytokinetics, Incorporated Quote CYTK\u2019 Zacks Rank & Stocks to Consider Cytokinetics currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the sector are Castle Biosciences CSTL, BioMarin Pharmaceutical BMRN and CytomX Therapeutics CTMX. While CSTL and BMRN currently sport a Zacks Rank #1 (Strong Buy) each, CTMX carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here . In the past 30 days, Castle Biosciences\u2019 earnings estimates for 2024 have increased from 34 cents to 39 cents per share. During the same timeframe, loss per share for 2025 has remained constant at $1.84. In the past three months, shares of Castle Biosciences have plunged 16.3%. CSTL\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%. In the past 30 days, estimates for BioMarin Pharmaceutical\u2019s 2024 earnings per share have Improved from $3.28 to $3.29. Estimates for 2025 earnings per share have decreased from $4.05 to $4.02 during the same timeframe. In the past three months, BioMarin Pharmaceutical shares have lost 11.9%. BMRN\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 28.7%. In the past 30 days, estimates for CytomX Therapeutics\u2019 2024 loss per share have remained constant at 5 cents. Estimates for 2025 loss per share have remained constant at 35 cents during the same timeframe. In the past three months, shares of CytomX Therapeutics have lost 22.4%. CTMX\u2019s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 115.70%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report Cytokinetics, Incorporated (CYTK) : Free Stock Analysis Report CytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report Castle Biosciences, Inc. (CSTL) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CYTK", "date": "2025-01-23T19:19:00", "sentiment": {"score": 0.4275383949279785, "confidence": 0.5761318206787109, "probabilities": {"positive": 0.5761318206787109, "negative": 0.14859342575073242, "neutral": 0.27527475357055664}}, "embedding": [-0.06593118607997894, -0.04532856494188309, -0.010380471125245094, -0.07221843302249908, 0.017437588423490524, -0.034834641963243484, -0.146497905254364, 0.30026185512542725, 0.0770333856344223, -0.005706056021153927, -0.04951607808470726, -0.016365280374884605, 0.09657905995845795, 0.033622317016124725, -0.035750146955251694, -0.03081287257373333, 0.11760632693767548, 0.13099542260169983, -0.13457977771759033, 0.11533640325069427, -0.05721329152584076, -0.009046501480042934, 0.037791356444358826, 0.08616189658641815, -0.12076733261346817, 0.015560832805931568, -0.174166738986969, 0.03404688835144043, -0.13032229244709015, 0.043732430785894394, 0.00886203721165657, 0.10509276390075684, 0.09077562391757965, 0.09399862587451935, 0.02204795368015766, 0.05845009535551071, -0.14523369073867798, -0.046862080693244934, -0.1749987006187439, -0.03821524977684021, 0.025075599551200867, -0.07257198542356491, -0.13611473143100739, 0.05940622091293335, 0.18960775434970856, -0.06370677798986435, -0.07412727177143097, 0.003447785973548889, -0.0963391661643982, 0.17091865837574005, -0.1243855208158493, -0.03970174863934517, 0.04347006231546402, 0.1468888819217682, -0.07264341413974762, -0.009760403074324131, -0.28255078196525574, -0.031876809895038605, 0.10371999442577362, 0.004426200874149799, -0.10241873562335968, 0.048464298248291016, -0.060138039290905, -0.035731032490730286, 0.09842464327812195, 0.025785785168409348, -0.037246670573949814, 0.012669207528233528, 0.04974669963121414, -0.03930013254284859, 0.0655876025557518, -0.13425037264823914, -0.05299726128578186, 0.11855369061231613, -0.0160366240888834, 0.14237472414970398, 0.0909212976694107, 0.05004020780324936, -0.033659979701042175, -0.2263716459274292, 0.0912792906165123, 0.042336881160736084, 0.030313873663544655, 0.0008550863713026047, -0.04975200444459915, 0.037051185965538025, 0.013793842867016792, 0.1717321127653122, -0.03014529123902321, 0.08496399223804474, 0.18811042606830597, 0.08097457885742188, 0.0705505833029747, -0.027226123958826065, 0.048887647688388824, -0.05638926848769188, -0.05096288025379181, 0.07673698663711548, 0.008976318873465061, -0.020173553377389908, 0.09279847145080566, 0.018166808411478996, -0.15857450664043427, -0.147507905960083, 0.021740611642599106, -0.13514727354049683, 0.08120764791965485, -0.06091861426830292, 0.12018679082393646, 0.008464044891297817, -0.019995957612991333, -0.03865249827504158, -0.050161704421043396, -0.09527992457151413, 0.10734766721725464, 0.31137681007385254, 0.011747753247618675, -0.007661512121558189, 0.28381651639938354, 0.07289405912160873, 0.07854609191417694, -0.1226557046175003, 0.05559180676937103, -0.1012226939201355, -0.09118899703025818, 0.13194367289543152, -0.1301664113998413, 1.3879796484128013e-32, -0.0051997946575284, 0.03833046928048134, 0.12008177489042282, 0.004618734121322632, 0.03905510529875755, -0.14210423827171326, 0.10904235392808914, -0.09432058036327362, -0.05124623328447342, -0.14263707399368286, -0.14271482825279236, 0.015609508380293846, -0.035619571805000305, -0.02786586806178093, -0.2346135377883911, -0.10478726774454117, -0.11830765008926392, -0.015356507152318954, -0.04760037735104561, 0.09401514381170273, 0.07523941993713379, -0.06431274116039276, -0.058598123490810394, -0.00541405426338315, -0.02999228611588478, 0.0748034119606018, -0.048977818340063095, 0.14801642298698425, -0.04403636232018471, 0.06346117705106735, -0.10273781418800354, 0.027259349822998047, -0.05463540554046631, -0.15524612367153168, -0.09427924454212189, -0.173774853348732, -0.06451630592346191, -0.04990723356604576, 0.025541219860315323, 0.010621817782521248, -0.12418610602617264, -0.018742412328720093, -0.07928647100925446, -0.07739433646202087, 0.1990131139755249, -0.0950232446193695, -0.01766200363636017, 0.004366549663245678, -0.07296306639909744, -0.003461184911429882, 0.08261141180992126, -0.08825592696666718, 0.010279593989253044, -0.06753337383270264, -0.05737348273396492, 0.06823166459798813, -0.10389585793018341, -0.06047225743532181, 0.019714457914233208, 0.06256479769945145, -0.00023895315825939178, 0.04154043644666672, 0.020857704803347588, 0.07849544286727905, -0.073310986161232, 0.09245432913303375, -0.14878466725349426, -0.10067176818847656, -0.2192651629447937, 0.0984470471739769, -0.0021552415564656258, -0.05107572674751282, 0.15456144511699677, -0.045831430703401566, 0.21009762585163116, -0.03215574473142624, -0.0038178032264113426, 0.245301753282547, -0.0759086161851883, -0.03560139238834381, -0.006547882221639156, 0.010356420651078224, -0.11775219440460205, 0.06225217506289482, 0.028032079339027405, -0.13606566190719604, 0.08101990073919296, -0.01619013398885727, -0.1899661272764206, -0.0836397185921669, 0.11919460445642471, -0.10842391848564148, 0.016983581706881523, 0.14627565443515778, 0.030274176970124245, -1.4258067627486748e-32, -0.0522952526807785, 0.10905726253986359, 0.021377326920628548, -0.08602681756019592, 0.011593693867325783, 0.08836572617292404, 0.14550963044166565, -0.12571042776107788, 0.24864569306373596, -0.03362150117754936, 0.1331017166376114, 0.014921926893293858, -0.03974518924951553, 0.009813034906983376, -0.16007643938064575, 0.09535413235425949, -0.13831663131713867, -0.024137752130627632, -0.09585326910018921, 0.16265162825584412, 0.05514370650053024, -0.04272904992103577, -0.06690290570259094, 0.2448771595954895, 0.0813552662730217, 0.09537485241889954, 0.04311851039528847, 0.10045797377824783, 0.11032092571258545, -0.11967248469591141, 0.07883420586585999, -0.015403086319565773, -0.21475130319595337, 0.025327663868665695, 0.03485056757926941, -0.09236747026443481, -0.04821326583623886, -0.07557148486375809, -0.048181816935539246, -0.1056557297706604, -0.016771692782640457, 0.006434004753828049, 0.02713354304432869, 0.0028915414586663246, -0.017404694110155106, 0.09225883334875107, 0.24836048483848572, -0.18156611919403076, 0.053963553160429, 0.029147852212190628, -0.016193479299545288, 0.05343346670269966, 0.02101496420800686, 0.2255019247531891, -0.0686366856098175, 0.09550460427999496, 0.16270795464515686, 0.18027637898921967, -0.12175990641117096, 0.06748935580253601, -0.0028901053592562675, 0.007545219734311104, 0.10186970233917236, 0.011290904134511948, 0.11205461621284485, -0.01944679021835327, 0.08860962092876434, 0.10519132018089294, 0.08077654242515564, -0.029813170433044434, -0.0056817978620529175, 0.00999823771417141, 0.06333251297473907, -0.10384973883628845, 0.029672538861632347, 0.12407178431749344, 0.062250711023807526, -0.12626856565475464, -0.19257304072380066, -0.057618558406829834, 0.0011101551353931427, -0.07591269910335541, -0.09559288620948792, -0.04102377966046333, -0.067786805331707, -0.031131545081734657, 0.13631263375282288, -0.02591569349169731, -0.02346557006239891, 0.013664823956787586, -0.07600469142198563, -0.03658425807952881, -0.07264483720064163, 0.15023818612098694, 0.05018836259841919, -1.005478438287355e-07, 0.07043441385030746, -0.10532199591398239, -0.09315770864486694, -0.13702696561813354, -0.03724300488829613, -0.1029013842344284, -0.035953786224126816, -0.007486026734113693, -0.1428602933883667, 0.0798858106136322, 0.04801471158862114, 0.13888034224510193, -0.04924356937408447, -0.15547442436218262, -0.044790007174015045, -0.14119480550289154, 0.013874208554625511, 0.025300247594714165, 0.026685509830713272, 0.060386937111616135, 0.012021387927234173, -0.04480741173028946, 0.06433379650115967, -0.08114359527826309, 0.07906176149845123, -0.0545736625790596, 0.07772229611873627, 0.11266961693763733, 0.04576529562473297, -0.04815969616174698, 0.09438014030456543, -0.005309123545885086, 0.04143638163805008, 0.09458381682634354, -0.055415548384189606, -0.04931219294667244, -0.036419518291950226, 0.01929597742855549, -0.011529582552611828, 0.12224417924880981, -0.007575556635856628, -0.15411147475242615, -0.0537940189242363, -0.020794574171304703, 0.0162767693400383, -0.04237579554319382, -0.0067381830886006355, -0.02831438183784485, 0.05961466580629349, -0.03414024040102959, -0.02757144719362259, 0.05033225938677788, -0.08677228540182114, -0.12514778971672058, 0.05310235172510147, 0.11073842644691467, -0.12414167821407318, -0.0027133990079164505, -0.0036381958052515984, -0.14415717124938965, 0.011043133214116096, -0.07662792503833771, 0.06215210631489754, 0.05327757075428963], "changes": {"1wk": 4.408693237448881}}, {"text": "Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst Vandana Singh Wed, Jan 22, 2025, 11:43 PM 2 min read In This Article: CYTK -2.01% Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst Stifel initiated coverage on Cytokinetics Incorporated (NASDAQ: CYTK ), noting the company\u2019s catalyst rich one to two years. The M&A speculation ramped up in early 2024 after the company released SEQUOIA-HCM Phase 3 trial data of\u00a0aficamten in December 2023. However, last year, Novartis AG (NYSE: NVS ) decided to step back from pursuing the\u00a0Cytokinetics deal . Amgen Inc (NASDAQ: AMGN ), AstraZeneca Plc (NASDAQ: AZN ), and Johnson & Johnson (NYSE: JNJ ) also all popped up as potential suitors, though the stock faded from there as a deal never materialized. Also Read: Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study Cytokinetics has fallen out of favor with investors after a turbulent start to 2024, marked by a controversial Royalty Pharma Plc (NASDAQ: RPRX ) deal and no mergers or acquisitions . Investors poorly received the structure of the Royalty Pharma deal at the time, and it continues to be a concern for many even today. Stifel has initiated coverage with a Buy rating and a price forecast of $80 . However, the outlook appears promising, with its valuation adjusted and several catalysts expected over the next 12+ months. Stifel analyst James Condulis writes Cytokinetics\u2019 aficamten is an exceptional drug as it sets a strong competitive standard for a multi-billion-dollar obstructive hypertrophic cardiomyopathy (oHCM) market. As the rollout of Bristol Myers Squibb Co\u2019s (NYSE: BMY ) Camzyos mavacamten continues, some concerns remain about its potential in treating obstructive hypertrophic cardiomyopathy (oHCM). While the initial launch is not seen as a negative sign for mavacamten\u2019s potential, its Risk Evaluation and Mitigation Strategy (REMS) is a barrier to fully unlocking the market. Cytokinetics appears well-positioned to capitalize on Bristol Myers\u2019 groundwork with its second-to-market drug, aficamten, which is expected to have a best-in-class profile. There is a strong case for aficamten to secure a differentiated REMS, potentially including six-month echocardiograms (Q6M echos) as a standard. Under conservative assumptions, aficamten could drive the U.S. oHCM market to approximately $3 billion. Looking ahead to 2025 and 2026, Phase 3 nHCM data and early findings for HFpEF could present new opportunities. Although mergers and acquisitions are not a key focus, potential strategic interest could bring unexpected benefits. Price Action: CYTK stock is up 3.45% at $47.40 at last check Wednesday. Read Next: Halliburton Faces Mixed Q4 With North American Weakness, But Global Gains And Cash Flow Bolster Optimism Story Continues Latest Ratings for CYTK Date Firm Action From To Dec 2021 Oppenheimer Initiates Coverage On Outperform Dec 2021 HC Wainwright & Co. Maintains Buy Dec 2021 JP Morgan Initiates Coverage On Overweight View More Analyst Ratings for CYTK View the Latest Analyst Ratings UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily , plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? CYTOKINETICS (CYTK): Free Stock Analysis Report This article Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst originally appeared on Benzinga.com \u00a9 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CYTK", "date": "2025-01-22T23:43:50", "sentiment": {"score": 0.674386702477932, "confidence": 0.7550502419471741, "probabilities": {"positive": 0.7550502419471741, "negative": 0.0806635394692421, "neutral": 0.16428624093532562}}, "embedding": [-0.06067802384495735, -0.10173866897821426, -0.024209972470998764, -0.0042687575332820415, 0.022105440497398376, 0.004905619192868471, -0.08626142144203186, 0.27444887161254883, 0.12208455055952072, 0.008008383214473724, -0.14288808405399323, 0.10628874599933624, 0.04753910377621651, 0.022573336958885193, -0.04041988402605057, 0.02712271362543106, 0.13878381252288818, 0.06589920818805695, -0.05789043754339218, 0.18974295258522034, -0.05208723992109299, -0.026472706347703934, 0.02999032661318779, 0.06881261616945267, -0.013366999104619026, 0.03558460623025894, -0.08325455337762833, -0.01902364194393158, -0.14495640993118286, -0.030013885349035263, 0.037722621113061905, 0.13345786929130554, 0.11953187733888626, 0.0810600221157074, 0.007875993847846985, 0.024145517498254776, -0.09001176059246063, -0.012861719354987144, -0.1361776441335678, -0.025244027376174927, 0.010933908633887768, -0.02245035581290722, -0.14461620151996613, 0.11657194793224335, 0.0816425234079361, -0.12429285049438477, 0.009925647638738155, -0.04407283291220665, 0.011156855151057243, 0.11281883716583252, -0.1574631631374359, -0.16259759664535522, -0.029543420299887657, 0.01209481991827488, -0.06500501930713654, 0.04636676609516144, -0.34027546644210815, -0.058693401515483856, 0.10398264974355698, -0.026209328323602676, 0.04977266490459442, 0.017728766426444054, 0.0054925307631492615, -0.007856752723455429, 0.08833146840333939, 0.03300945460796356, 0.02459537237882614, 0.1041877418756485, 0.07605120539665222, -0.035570837557315826, 0.17007037997245789, -0.13804149627685547, -0.00789027102291584, 0.04275762289762497, -0.11738156527280807, 0.2427055835723877, 0.1602952480316162, 0.01284162700176239, 0.1112024337053299, -0.08499748259782791, 0.08021530508995056, 0.0015683970414102077, 0.038512829691171646, -0.04758274555206299, 0.028037257492542267, 0.05774182453751564, 0.01435830444097519, 0.1530211865901947, 0.1185024082660675, 0.005499842576682568, 0.172785684466362, 0.045549094676971436, 0.060610316693782806, 0.0347306951880455, 0.02876579575240612, -0.05172891169786453, 0.0010487115941941738, 0.0038052890449762344, 0.043101366609334946, 0.003697287291288376, 0.09794613718986511, 0.15625473856925964, -0.12841366231441498, -0.04153599217534065, 0.0014601591974496841, -0.14347687363624573, 0.0811849981546402, -0.07898879051208496, 0.13186456263065338, 0.009812064468860626, -0.07870376110076904, 0.0013956660404801369, -0.10392215847969055, -0.13204699754714966, -0.06343001872301102, 0.27928411960601807, -0.036916717886924744, -0.007306277751922607, 0.17382748425006866, 0.048353664577007294, 0.047660477459430695, -0.06906689703464508, -0.025482654571533203, -0.10911357402801514, 0.03438427299261093, 0.1552729457616806, -0.24372830986976624, 1.31511045973174e-32, -0.07951641082763672, 0.1276346743106842, 0.10207973420619965, 0.04600682109594345, 0.005180055275559425, 0.0030194090213626623, 0.10587415844202042, -0.10030845552682877, -0.1303219199180603, -0.10596795380115509, -0.2405308485031128, 0.08826941251754761, -0.05365139991044998, -0.037300847470760345, -0.12327226996421814, -0.19886502623558044, -0.12197672575712204, -0.04993826895952225, 0.03951512649655342, -0.042531825602054596, -0.01516165491193533, 0.009491557255387306, -0.07833290100097656, 0.028985412791371346, -0.14163975417613983, 0.04746466875076294, 0.010141436010599136, 0.08110594749450684, 0.12135427445173264, 0.059488728642463684, -0.06968227028846741, -0.010491302236914635, -0.04213032126426697, -0.04272792115807533, -0.07035985589027405, -0.047066543251276016, -0.18694782257080078, -0.13554489612579346, 0.030181610956788063, -0.036885347217321396, -0.19585588574409485, 0.08119480311870575, -0.10407906770706177, -0.12694139778614044, 0.10989882051944733, -0.1214742362499237, -0.11946552991867065, -0.048133064061403275, -0.04459475725889206, -0.06677446514368057, 0.02258225530385971, 0.03856338933110237, -0.010563084855675697, -0.04581230878829956, -0.06366150826215744, 0.024176761507987976, -0.13017940521240234, -0.0024537276476621628, -0.010667548514902592, 0.119185671210289, -0.0047880904749035835, 0.03876502811908722, 0.008892256766557693, 0.057179536670446396, -0.10779611766338348, 0.24474072456359863, -0.12392669916152954, -0.034987498074769974, -0.2252528965473175, 0.20811183750629425, 0.12006591260433197, -0.04333928972482681, 0.09847759455442429, -0.057181499898433685, 0.1440258026123047, 0.0027994103729724884, 0.04176218807697296, 0.1979561746120453, 0.0067769004963338375, -0.06974238157272339, 0.005815020762383938, 0.010507956147193909, -0.05621833726763725, 0.12658677995204926, 0.007427293807268143, -0.1267642378807068, 0.08176274597644806, -0.020685384050011635, -0.13357122242450714, 0.04595639929175377, 0.159245103597641, -0.08361190557479858, 0.0028644241392612457, 0.1781020164489746, -0.026621460914611816, -1.1907959077237351e-32, -0.07100391387939453, 0.06650955975055695, -0.0011801193468272686, -0.13440248370170593, -0.08106294274330139, 0.03201798349618912, 0.12964637577533722, -0.06261321157217026, 0.08616278320550919, -0.12125223129987717, 0.08393078297376633, 0.03342592343688011, -0.05681958794593811, 0.12099580466747284, -0.15439672768115997, 0.010798845440149307, 0.0674658939242363, -0.15917465090751648, -0.0353899821639061, -0.0018829654436558485, 0.02101694606244564, 0.11708830296993256, -0.12719690799713135, 0.22699785232543945, 0.007460668217390776, 0.11585143208503723, 0.07954093813896179, 0.03888311982154846, -0.03016328439116478, -0.0837131142616272, 0.03937442600727081, 0.0004425155930221081, -0.2168164998292923, 0.030739113688468933, 0.01438091229647398, 0.09002697467803955, -0.03824000060558319, -0.04332781583070755, -0.06864593923091888, -0.12790390849113464, 0.011753791943192482, 0.03332457318902016, 0.02850927971303463, 0.041553739458322525, 0.05577867478132248, 0.05610888451337814, 0.19723477959632874, -0.04456666111946106, 0.25638025999069214, 0.02027789130806923, -0.08882483839988708, 0.00848936103284359, 0.033543460071086884, 0.08638550341129303, -0.06607330590486526, 0.044930871576070786, 0.09552096575498581, 0.04352469742298126, -0.12625816464424133, -0.00017223553732037544, 0.014048868790268898, 0.04078243672847748, 0.11329467594623566, -0.13784091174602509, 0.10083919763565063, 0.10379267483949661, 0.17259714007377625, -0.016071444377303123, 0.03176990896463394, -0.1315731555223465, 0.05381105840206146, 0.0225213672965765, -0.10585599392652512, -0.045662544667720795, -0.01185669470578432, 0.10350429266691208, -0.004143205471336842, -0.16120341420173645, -0.2079683542251587, -0.12604928016662598, 0.04977528005838394, -0.07936125993728638, -0.021429628133773804, -0.04129793494939804, 0.03364366292953491, 0.01181863248348236, 0.13964474201202393, -0.003414271865040064, -0.049013711512088776, 0.02677581086754799, -0.08734825253486633, -0.13108840584754944, -0.10436506569385529, 0.1632256805896759, 0.0498485192656517, -9.999573080676782e-08, 0.05999124050140381, -0.05651656538248062, -0.017398951575160027, -0.1806524395942688, 0.09088066220283508, -0.05009801685810089, -0.042029138654470444, -0.004978537559509277, 0.010440600104629993, 0.1859048753976822, 0.07757364213466644, 0.13492324948310852, -0.11452951282262802, -0.04439648240804672, -0.06997737288475037, 0.004153032321482897, -0.12754052877426147, 0.008572477847337723, 0.005004175007343292, -0.018273798748850822, -0.09807334840297699, 0.06685508787631989, 0.019381863996386528, -0.05904107913374901, 0.09600585699081421, -0.09998133778572083, 0.037129584699869156, 0.09913668036460876, 0.08198796212673187, -0.01858336851000786, 0.06165577098727226, 0.000317305326461792, 0.18547192215919495, 0.07886335253715515, -0.1484616994857788, -0.16294771432876587, 0.07167305052280426, 0.10300345718860626, 0.045567966997623444, 0.06215686351060867, -0.030358271673321724, -0.03275085240602493, -0.050075843930244446, 0.029517540708184242, -0.11119215190410614, -0.09666144102811813, -0.07684358209371567, -0.0242453683167696, 0.07368864119052887, -0.079508475959301, 0.03512461110949516, -0.014077131636440754, -0.031091222539544106, -0.05476158857345581, -0.003296135924756527, -0.006975636351853609, -0.16860844194889069, 0.05628223344683647, -0.028637506067752838, -0.05597129091620445, -0.024857528507709503, -0.30271321535110474, 0.09089705348014832, 0.09646131098270416], "changes": {"1wk": 3.9085900106423694}}, {"text": "Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction Cytokinetics, Incorporated Tue, Jan 21, 2025, 3:30 PM 8 min read In This Article: CYTK -2.01% Cytokinetics, Incorporated SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- \u00a0Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that AMBER-HFpEF ( A ssessment of CK-586 in a M ulti-Center, B linded E valuation of Safety and Tolerability R esults in HFpEF ) is open to enrollment. AMBER-HFpEF is a Phase 2 randomized, placebo-controlled, double-blind, multi-center, dose-finding clinical trial of CK-4021586 (CK-586) in patients with symptomatic heart failure with preserved ejection fraction (HFpEF) with left ventricular ejection fraction (LVEF) \u226560%. CK-586 is a cardiac myosin inhibitor in development for the potential treatment of a subgroup of with symptomatic HFpEF patients with hypercontractility and ventricular hypertrophy. \u201cWe are pleased to be advancing CK-586 into a Phase 2 trial in a subset of patients with symptomatic HFpEF,\u201d said Stuart Kupfer, M.D., Senior Vice President, Chief Medical Officer. \u201cDespite recent advances in available treatments, patients with heart failure with supranormal ejection fraction continue to have a poor prognosis following hospitalization. Evaluating CK-586 in this Phase 2 trial further extends the potential of our cardiac myosin directed development platform focused to specialty cardiology indications.\u201d Approximately half of patients with heart failure have HFpEF, characterized by an ejection fraction of at least 50%, impaired diastolic function and elevated NTpro-BNP, which can lead to poor ventricular compliance and reduced cardiac output. A subset of patients with HFpEF resemble patients with non-obstructive hypertrophic cardiomyopathy (nHCM) in that those patients have higher ejection fractions and thickened walls of their heart in association with elevated cardiac biomarkers and symptoms of heart failure. The evaluation of CK-586 in HFpEF builds on the similarity of these conditions and the data accumulated to date with aficamten in nHCM. About AMBER-HFpEF AMBER-HFpEF is a Phase 2 randomized, placebo-controlled, double-blind, multi-center, dose-finding clinical trial in patients with symptomatic HFpEF with LVEF \u226560%. The primary objective is to evaluate the safety and tolerability profile of CK-586 compared to placebo. The secondary objectives include assessing the effect of CK-586 on LVEF and NT-proBNP, and determining both its pharmacokinetics and its pharmacokinetic/pharmacodynamic relationship. A number of exploratory endpoints will evaluate the effect of CK-586 on patient function, symptoms, and measures of cardiac function. AMBER-HFpEF is planned to enroll approximately 60 patients randomized on a 3:1 basis to receive CK-586 or placebo in three dose escalation cohorts. Patients will receive up to two escalating doses of CK-586 over 12 weeks or placebo. An echocardiogram at Week 6 will determine whether patients will be up-titrated to the higher dose. Once-daily doses of 150 mg and 300 mg are planned in Cohort 1, 300 mg and 450 mg in Cohort 2 and 450 mg and 600 mg in Cohort 3. At screening, patients enrolled in AMBER-HFpEF must have LVEF \u226560%, NT-proBNP \u2265300 pg/mL for participants in sinus rhythm and \u2265900 pg/mL for participants with atrial fibrillation or flutter (AFF), and be New York Heart Association (NYHA) Functional Class II or III. Additional information can be found on www.clinicaltrials.gov . Story Continues About CK-4021586 (CK-586) CK-4021586 (CK-586) is designed to be a novel, selective, oral, small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction (HFpEF). CK-586 was designed to selectively inhibit the ATPase of intact cardiac myosin but does not inhibit the ATPase of subfragment-1 of myosin (S1). The inhibitory effect of CK-586 requires the presence of the regulatory light chain (RLC) of myosin in the context of the intact myosin dimer (heavy meromyosin or HMM). In preclinical models, CK-586 reduced cardiac hypercontractility by decreasing the number of active myosin cross-bridges during cardiac contraction thereby reducing the contractile force, without effect on calcium transients. In engineered human HCM heart tissues, CK-586 demonstrated shallow force-concentration response and improved lusitropy. A subset of patients with HFpEF resemble patients with non-obstructive hypertrophic cardiomyopathy (nHCM) in that those patients have higher ejection fractions, thickened walls of their heart, elevated biomarkers, and symptoms of heart failure.\u00a0Data from a Phase 2 clinical trial of aficamten, another investigational cardiac myosin inhibitor being developed by Cytokinetics, showed that in patients with nHCM aficamten was well tolerated, improved patient reported outcomes (Kansas City Cardiomyopathy Questionnaire (KCCQ) and New York Heart Association (NYHA) Functional Class) and biomarkers, measures that are also relevant to HFpEF. Aficamten was also well-tolerated with no drug discontinuations due to adverse events and no adverse events of heart failure. These data provide support for investigating this mechanism of action in HFpEF. About Heart Failure with Preserved Ejection Fraction Heart failure is a grievous condition that affects more than 64 million people worldwide. 1 Approximately 6.7 million Americans have heart failure, which is expected to increase to over 8.5 million Americans by 2030. 2 Approximately half of patients with heart failure have heart failure with preserved ejection fraction (HFpEF) 3 , and the prevalence of HFpEF is increasing. 2,4 Approximately 75% of patients with HFpEF will die within five years of initial hospitalization, and 84% will be rehospitalized. 2 Despite broad use of standard treatments and advances in care, the prognosis for patients with heart failure is poor. 5 A subset of HFpEF patients with hypercontractility, ventricular hypertrophy, elevated biomarkers and symptoms of heart failure may benefit from treatment with a cardiac sarcomere inhibitor. About Cytokinetics Cytokinetics is a late-stage, muscle biology specialty biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, Cytokinetics is intent on meaningfully improving the lives of patients through global access to innovative\u00a0medicines. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a potential next-in-class cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil , a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function. For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X , LinkedIn , Facebook and YouTube . Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the \"Act\"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements, express or implied, relating to the Company\u2019s development plans for CK-586 in the United States, including its ability to full enroll AMBER-HFpEF by any particular date, if at all. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics' drug candidates that could slow or prevent clinical development or product approval; Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics' ability to conduct clinical trials; Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; standards of care may change, rendering Cytokinetics' drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics' drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission. CYTOKINETICS \u00ae and the C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries. References: James et al. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Lancet 2018; 392: 1789\u2013858. Bozkurt B, Ahmad T, Alexander KM, Baker WL, Bosak K, Breathett K, Fonarow GC, Heidenreich P, Ho JE, Hsich E, Ibrahim NE, Jones LM, Khan SS, Khazanie P, Koelling T, Krumholz HM, Khush KK, Lee C, Morris AA, Page RL 2nd, Pandey A, Piano MR, Stehlik J, Stevenson LW, Teerlink JR, Vaduganathan M, Ziaeian B; Writing Committee Members. Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America. J Card Fail. 2023 Oct;29(10):1412-1451. doi: 10.1016/j.cardfail.2023.07.006. Epub 2023 Sep 26. PMID: 37797885; PMCID: PMC10864030. Dunlay SM, Roger VL, Weston SA, Jiang R, Redfield MM. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail. 2012 Nov;5(6):720-6. doi: 10.1161/CIRCHEARTFAILURE.111.966366. Epub 2012 Aug 30. PMID: 22936826; PMCID: PMC3661289. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart failure: A Report of the\u00a0American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.\u00a0Circulation. 2013;128:e240-e327. Jhund PS, MacIntyre K, Simpson CR, et al. Long-Term Trends in First Hospitalization for Heart Failure and Subsequent Survival Between 1986 and 2003.\u00a0Circulation. 2009;119:515-523. Contact: Cytokinetics Diane Weiser Senior Vice President, Corporate Affairs (415) 290-7757 View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CYTK", "date": "2025-01-21T15:30:00", "sentiment": {"score": 0.2323281317949295, "confidence": 0.3004748523235321, "probabilities": {"positive": 0.3004748523235321, "negative": 0.0681467205286026, "neutral": 0.6313783526420593}}, "embedding": [-0.0232155229896307, -0.050973840057849884, 0.05701644346117973, -0.05069781839847565, 0.08148513734340668, -0.016537664458155632, -0.17917698621749878, 0.20317846536636353, 0.021355830132961273, -0.011931976303458214, -0.01400526612997055, -0.05990099161863327, 0.07605750858783722, 0.048779409378767014, -0.010304146446287632, -0.025419801473617554, 0.12707635760307312, 0.18664629757404327, -0.1909841001033783, 0.10977781563997269, -0.008704819716513157, 0.023551765829324722, 0.015660513192415237, 0.08592811226844788, -0.05269274488091469, 0.024234391748905182, -0.27788880467414856, -0.01132968533784151, -0.10796089470386505, 0.004213778767734766, 0.05554290860891342, 0.029241900891065598, 0.029139336198568344, 0.19240984320640564, -0.018908938392996788, 0.07648087292909622, -0.11967648565769196, -0.05173908919095993, -0.19256189465522766, -0.04102953150868416, 0.004767453297972679, -0.057349786162376404, -0.14182507991790771, 0.028917064890265465, 0.1676989197731018, -0.07299631834030151, -0.06925368309020996, -0.009433610364794731, -0.08549591898918152, 0.2018028050661087, -0.1017201766371727, -0.016756396740674973, 0.03336188942193985, 0.08324184268712997, -0.0065812766551971436, -0.02754596620798111, -0.20149895548820496, -0.1268528252840042, 0.12862908840179443, -0.018275227397680283, -0.10156398266553879, -0.039452504366636276, -0.03276875615119934, -0.07652930915355682, 0.07461538910865784, -0.008864449337124825, -0.03269060701131821, -0.0621626041829586, 0.0420498251914978, 0.023231878876686096, 0.08180457353591919, -0.09012751281261444, -0.0901305228471756, 0.19427302479743958, 0.09103472530841827, 0.1369898021221161, 0.02567550539970398, -0.01582825556397438, -0.06377749145030975, -0.11404356360435486, 0.11666485667228699, 0.08080621808767319, -0.008520533330738544, -0.041988126933574677, 0.0012764325365424156, 0.03704740107059479, -0.026717958971858025, 0.14812153577804565, -0.023381691426038742, 0.034776829183101654, 0.220210462808609, 0.06580653041601181, 0.1311483085155487, -0.02029310166835785, 0.1435030996799469, -0.10414336621761322, -0.015580612234771252, 0.06733183562755585, -0.022594884037971497, -0.02003275416791439, 0.0860636830329895, 0.01967259868979454, -0.2007288932800293, -0.17151017487049103, 0.13199427723884583, -0.11889854818582535, 0.005114411935210228, -0.029245004057884216, 0.09232629835605621, 0.0014303335919976234, 0.10025712102651596, -0.04774600639939308, 0.02000579796731472, -0.02015528455376625, 0.10740898549556732, 0.2546067535877228, -0.06057252734899521, -0.00651458278298378, 0.19218051433563232, 0.09122307598590851, 0.12196947634220123, -0.12685585021972656, 0.02535076066851616, -0.09125292301177979, -0.06147008016705513, 0.15144607424736023, -0.10610529780387878, 9.382803255103192e-33, 0.09185105562210083, 0.06558689475059509, 0.06331084668636322, 0.0771401971578598, 0.11359803378582001, -0.21333813667297363, 0.021244611591100693, -0.10830289870500565, -0.09075742214918137, -0.07855626940727234, -0.12562696635723114, 0.059000492095947266, -0.01476683747023344, -0.03327897936105728, -0.2280082106590271, -0.06869834661483765, -0.0887453705072403, -0.03746761381626129, -0.027497250586748123, 0.10259079933166504, 0.11240485310554504, -0.02891671285033226, -0.045522987842559814, -0.12126976251602173, -0.09442625939846039, 0.12062126398086548, 0.008232289925217628, 0.2071731835603714, -0.01875433698296547, 0.005805810913443565, -0.09529906511306763, -0.029126286506652832, 0.016409127041697502, -0.10471351444721222, -0.0780060663819313, -0.2156940996646881, -0.03474775329232216, -0.021705232560634613, -0.03552067279815674, 0.004069262184202671, -0.10629422217607498, 0.0356016606092453, -0.13719259202480316, -0.06636272370815277, 0.22832083702087402, -0.21782207489013672, 0.05187824368476868, -0.08276534080505371, -0.12615475058555603, 0.04282601550221443, 0.09930063784122467, -0.06948640942573547, 0.08379845321178436, -0.01997210644185543, -0.024215012788772583, 0.02953173778951168, -0.0296950526535511, -0.013970248401165009, 0.04868118092417717, 0.025652609765529633, -0.0439685583114624, 0.06609536707401276, 0.0005974322557449341, 0.09071056544780731, -0.05406902730464935, 0.025512803345918655, -0.08294275403022766, -0.08715024590492249, -0.20117950439453125, 0.060571156442165375, 0.0871264860033989, -0.15602590143680573, 0.112251415848732, 0.03020048886537552, 0.11506790667772293, -0.009437916800379753, -0.042420923709869385, 0.19077476859092712, -0.11865672469139099, -0.086850106716156, -0.13268783688545227, 0.07133868336677551, -0.16778147220611572, 0.13038355112075806, 0.044513583183288574, -0.13801082968711853, 0.05048292875289917, -0.0067449756897985935, -0.2647971212863922, -0.17007231712341309, 0.14819253981113434, -0.10508280992507935, 0.0702943354845047, 0.0894690454006195, -0.024197623133659363, -1.0778727775959613e-32, -0.027951214462518692, 0.005013837944716215, 0.0029655499383807182, -0.11378642916679382, -0.013551358133554459, 0.12885619699954987, 0.1624772548675537, -0.16756249964237213, 0.17131438851356506, -0.09045054018497467, 0.1428976058959961, -0.046569257974624634, -0.006617830600589514, 0.0550750270485878, -0.15046393871307373, 0.08001803606748581, -0.15269994735717773, -0.013961405493319035, -0.09608553349971771, 0.2451220005750656, 0.09061978757381439, -0.023317430168390274, -0.08299178630113602, 0.22777995467185974, 0.08690754324197769, 0.16999971866607666, 0.11714686453342438, 0.1698715090751648, 0.09077291935682297, -0.2096310257911682, 0.12539945542812347, -0.1221441924571991, -0.1520189344882965, -0.09299936890602112, 0.03841055929660797, -0.08828820288181305, -0.005786031950265169, 0.0243084579706192, -0.026378346607089043, -0.04681883752346039, -0.01240807119756937, 0.05654381960630417, -0.024441104382276535, 0.05727069452404976, -0.03555391728878021, 0.0993926003575325, 0.20748673379421234, -0.1242666244506836, 0.05845768004655838, 0.043614186346530914, -0.08546556532382965, 0.03875451162457466, -0.029217185452580452, 0.21522274613380432, -0.11833132058382034, 0.0539853498339653, 0.13076326251029968, 0.23291932046413422, -0.14902248978614807, 0.09719035029411316, -0.029501376673579216, 0.026055173948407173, 0.11061535775661469, 0.020515697076916695, 0.17211733758449554, 0.05571341514587402, 0.057550545781850815, 0.11628691852092743, 0.03514508530497551, -0.04175880178809166, -0.024738408625125885, 0.040488630533218384, 0.025395283475518227, -0.09794814884662628, 0.09684737026691437, 0.07547768950462341, -0.030488204210996628, -0.060358092188835144, -0.1532050222158432, -0.07668175548315048, -0.02352447435259819, -0.10796462744474411, -0.14563146233558655, -0.025716885924339294, -0.028271928429603577, -0.023351985961198807, 0.1820608675479889, -0.0806017816066742, 0.06432973593473434, 0.0016675656661391258, -0.0065726637840271, -0.018935400992631912, -0.12864536046981812, 0.15188929438591003, -0.04724518582224846, -1.0025590313489374e-07, 0.051837991923093796, -0.05094040557742119, -0.0948110818862915, -0.2639525532722473, -0.07554745674133301, -0.11897315829992294, -0.029962124302983284, -0.057179540395736694, -0.20420493185520172, 0.0639454573392868, 0.08998085558414459, 0.09749516099691391, -0.03333108872175217, -0.22465497255325317, 0.01069677621126175, -0.1450187861919403, -0.01112430915236473, 0.06685309112071991, 0.018244920298457146, 0.011358155868947506, 0.07456482201814651, -0.06193745881319046, 0.08057881891727448, -0.1265750229358673, 0.06584294140338898, -0.014930058270692825, 0.14932578802108765, 0.10608331859111786, 0.05332406610250473, -0.11311513930559158, 0.004114209674298763, -0.02913637086749077, 0.11326315253973007, 0.12009148299694061, -0.019652295857667923, -0.06965850293636322, 0.010228712111711502, -0.043800707906484604, -0.016992362216114998, 0.07387371361255646, 0.0008044536225497723, -0.12816086411476135, -0.07938488572835922, -0.03912591561675072, -0.004606615751981735, -0.005855550989508629, 0.05724531412124634, 0.06436282396316528, 0.14474010467529297, -0.02818560227751732, -0.02275617979466915, 0.022678494453430176, -0.0621696338057518, -0.15359637141227722, 0.008072255179286003, 0.07348351925611496, -0.10541030764579773, 0.033365603536367416, 0.06012982130050659, -0.0611812025308609, 0.08986802399158478, -0.06899119913578033, 0.029994837939739227, 0.030117934569716454], "changes": {"1wk": 8.991704407082649}}, {"text": "Netflix upgraded, Reddit downgraded: Wall Street's top analyst calls The Fly Wed, Jan 22, 2025, 5:36 PM 4 min read In This Article: NFLX +0.22% RDDT +1.38% Netflix upgraded, Reddit downgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Rosenblatt upgraded Netflix (NFLX) to Buy from Neutral with a price target of $1,494, up from $680, after the company \"delivered on so many levels\" in Q4. Canaccord also upgraded Netflix to Buy from Hold with a price target of $1,150, up from $940, after the company reported strong Q4 results, with paid memberships, revenue, and profitability all coming in ahead of expectations. Meanwhile, Barclays upgraded Netflix to Equal Weight from Underweight with a price target of $900, up from $715, and Benchmark upgraded Netflix to Hold from Sell with no price target. Bernstein upgraded Darden (DRI) to Outperform from Market Perform with a price target of $215, up from $180. After a \"dismal 2024, the restaurants sector looks relatively inexpensive,\" the firm tells investors in a research note, adding that Darden has upside from improvements in its core middle-income consumer cohort, rollout of UberDirect with marketing support, and efficiency measures supporting margin expansion. Wells Fargo upgraded 3M (MMM) to Overweight from Equal Weight with a price target of $170, up from $140. The company is in the \"early days of significant margin expansion\" at a time of uncertainty about the trajectory of an industrial recovery, which is attractive, the firm tells investors in a research note. Summit Insights upgraded Seagate (STX) to Buy from Hold. The firm is positive on the company's HAMR HDD technology transition driving upside to its gross margin in the second half of FY25, also noting that the current favorable pricing environment and product mix at Seagate will continue. Barclays upgraded Hormel Foods (HRL) to Overweight from Equal Weight with a price target of $36, up from $35. The firm sees the company's investments into its \"Transform and Modernize\" initiative materializing into a higher long-term margin structure. Top 5 Downgrades: Roth MKM downgraded Reddit (RDDT) to Neutral from Buy with a price target of $195, up from $116. Given the rise in the share price, the firm believes the near-term risk/reward is fairly balanced at current levels. Barclays downgraded Ford (F) to Equal Weight from Overweight with a price target of $11, down from $13. The firm says that while it appreciates Ford's transformation efforts, it believes elevated volume headwinds in 2025 due to inventory destocking and continued modest price normalization will drive downside on earnings estimates. Stephens downgraded Elevance Health (ELV) to Equal Weight from Overweight with a price target of $440, down from $520. Despite the company having previously cut expectations in conjunction with its Q3 earnings report, the firm sees a \"formidable set of percolating risks\" to the current Street 2025 adjusted EPS forecast. Bernstein downgraded Yum! Brands (YUM) to Market Perform from Outperform with a price target of $135, down from $140. Yum may witness pressures in reaching its long-term growth algorithm in 2025, resulting in a range-bound stock, the firm tells investors in a research note. TD Cowen downgraded Celsius Holdings (CELH) to Hold from Buy with a price target of $29, down from $40. Celsius shares are already well below their highs, but the valuation multiple could contract even further if the company goes \"ex-growth,\" the firm tells investors in a research note. Story Continues Top 5 Initiations: Citi resumed coverage of Disney (DIS) with a Buy rating and $125 price target. While consensus earnings estimates \"look a touch high,\" the stock's risk/reward is attractive at prevailing levels, the firm tells investors in a research note. Stifel initiated coverage of Cytokinetics (CYTK) with a Buy rating and $80 price target. Cytokinetics \"is an out-of-favor stock\" following the \"controversial\" Royalty Pharma deal, but Stifel believes the stock's valuation has largely reset and with a catalyst-rich 12-months ahead. Goldman Sachs initiated coverage of Viking Holdings (VIK) with a Neutral rating and $49 price target. The firm sees a \"lot to like\" about Viking's business model, but with the stock up 73% since the initial public offering in May 2024, Goldman would look for a more favorable entry point at these levels. Truist initiated coverage of APi Group (APG) with a Buy rating and $45 price target. The firm says APi is an \"underappreciated name\" as it \"quietly\" holds the leading market position in U.S. fire protection. Craig-Hallum initiated coverage of Daktronics (DAKT) with a Buy rating and $26 price target. The firm sees a significant stock opportunity and the potential for a $35-$40 stock over time. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CYTK", "date": "2025-01-22T17:36:09", "sentiment": {"score": 0.9312058733776212, "confidence": 0.945905864238739, "probabilities": {"positive": 0.945905864238739, "negative": 0.01469999086111784, "neutral": 0.039394255727529526}}, "embedding": [-0.0800449475646019, -0.2351164072751999, -0.08102613687515259, 0.03355798125267029, 0.09831523150205612, -0.024612098932266235, -0.005788707174360752, 0.10251130163669586, 0.14881734549999237, 0.023064935579895973, -0.07991160452365875, 0.12822559475898743, -0.004263145849108696, -0.06047770380973816, 0.04994140565395355, -0.10896436870098114, 0.1670723855495453, -0.10361087322235107, -0.22840045392513275, 0.03905228152871132, -0.013494569808244705, -0.15250718593597412, -0.05429396405816078, -0.07389439642429352, 0.06698986887931824, 0.008243678137660027, -0.08297738432884216, -0.02479979582130909, -0.18293286859989166, -0.11552146077156067, -0.017785146832466125, 0.19799324870109558, 0.019624345004558563, -0.06116810441017151, -0.03693325072526932, -0.08221393823623657, -0.03285602852702141, 0.0017233856488019228, 0.047798044979572296, -0.04599083587527275, -0.07666867971420288, -0.03692048043012619, -0.10022595524787903, 0.04158132150769234, 0.04398482292890549, -0.1580512523651123, -0.023767877370119095, 0.11319389194250107, 0.08504553884267807, 0.002653254196047783, -0.17006249725818634, 0.09753035008907318, 0.0008337981998920441, -0.03222501650452614, -0.02048490196466446, 0.15159831941127777, -0.014196943491697311, 0.003482781583443284, 0.05792390555143356, -0.03109162300825119, 0.04548169672489166, -0.15107640624046326, 0.0694054514169693, 0.04121740907430649, 0.13599729537963867, -0.05023043975234032, -0.07240834832191467, -0.11056622862815857, -0.11887399852275848, 0.018816810101270676, 0.04450050741434097, -0.018697315827012062, -0.0642828643321991, -0.07807941734790802, 0.12443441152572632, 0.06893296539783478, 0.19543686509132385, -0.03495202586054802, 0.031267937272787094, -0.04247497767210007, 0.03381861746311188, -0.030577898025512695, 0.006852330639958382, -0.008096418343484402, -0.006795207038521767, -0.086196169257164, 0.08650016784667969, -0.04018120840191841, 0.021681275218725204, 0.013231301680207253, 0.05712916702032089, -0.005825132131576538, -0.07078493386507034, 0.025486186146736145, -0.02445213869214058, 0.01820431835949421, -0.12216857075691223, -0.05546704679727554, -0.0317513681948185, 0.046262502670288086, 0.15594178438186646, 0.0524238646030426, -0.046509966254234314, -0.04047681391239166, -0.04606492072343826, -0.16209807991981506, 0.11877533048391342, 0.1677035689353943, 0.041886549443006516, -0.049831971526145935, -0.0708046555519104, 0.06778901070356369, 0.006041103042662144, -0.02184867486357689, -0.1574743092060089, 0.007285581901669502, -0.009493375197052956, -0.11445770412683487, 0.13661301136016846, 0.06959657371044159, 0.06547094881534576, 0.1444428265094757, 0.0006472403183579445, 0.002696748822927475, -0.12148243188858032, 0.010420739650726318, -0.14499373733997345, 1.2550381433641116e-32, -0.09799899905920029, 0.010909771546721458, -0.0594710037112236, -0.24752551317214966, -0.0291910357773304, -0.019635550677776337, 0.11851866543292999, 0.1624586582183838, -0.118607297539711, -0.017379194498062134, -0.0722830519080162, 0.07221980392932892, -0.08468268811702728, -0.02597026154398918, 0.061966463923454285, -0.12506842613220215, -0.04637286812067032, 0.019705835729837418, 0.03869577497243881, -0.06376849859952927, 0.07369904965162277, 0.06569804251194, -0.008227351121604443, -0.01775391213595867, -0.03268953785300255, -0.10079163312911987, -0.021221887320280075, 0.06702297180891037, 0.09763485193252563, 0.07092709839344025, -0.06649237871170044, -0.04210673272609711, 0.023200098425149918, -0.10710708796977997, -0.04546729475259781, -0.06995324045419693, -0.10247303545475006, -0.104946568608284, 0.009761318564414978, -0.009121472015976906, -0.24494561553001404, 0.20109650492668152, -0.14997932314872742, -0.0717373788356781, -0.0651579424738884, 0.04271877184510231, 0.022054173052310944, 0.044790416955947876, -0.1555425524711609, 0.05479490011930466, -0.1076640635728836, 0.04575584456324577, 0.016306348145008087, -0.033582206815481186, -0.11520877480506897, -0.0014480352401733398, 0.022695615887641907, -0.06960824131965637, 0.02472774311900139, 0.08462370932102203, 0.08310829102993011, 0.0802425667643547, -0.0968560203909874, -0.005000049713999033, -0.15901902318000793, 0.2234063744544983, 0.1561654955148697, 0.07967283576726913, -0.0866817981004715, 0.17833620309829712, 0.04895498603582382, 0.03918544575572014, 0.12649454176425934, 0.00942927971482277, 0.13989894092082977, -0.0876232236623764, -0.05593197047710419, 0.03795883432030678, 0.12646394968032837, -0.07584240287542343, 0.07172902673482895, 0.07692798227071762, 0.07722242921590805, 0.017085257917642593, -0.17959317564964294, 0.030205905437469482, -0.010063555091619492, -0.036769505590200424, -0.02642086148262024, -0.011809288524091244, -0.022663481533527374, -0.007781057618558407, -0.024037856608629227, 0.04588615894317627, 0.10256610065698624, -1.1402121817559443e-32, -0.10158178210258484, -0.03719574585556984, -0.099864661693573, 0.04063263535499573, -0.0927039086818695, 0.003802298568189144, -0.0380980409681797, -0.07070174068212509, 0.08220203965902328, -0.05209611728787422, -0.10525092482566833, 0.08856379240751266, -0.0740102156996727, 0.0163034126162529, -0.09537284076213837, -0.05654975771903992, -0.07228920608758926, -0.1413632333278656, -0.02428669109940529, -0.021765410900115967, 0.0602673664689064, 0.18130093812942505, -0.11409436166286469, 0.13824068009853363, 0.0575813427567482, 0.07572834193706512, -0.005424391478300095, 0.23962420225143433, 0.02573966607451439, -0.06582076847553253, -0.030347593128681183, -0.0913643091917038, -0.09523381292819977, 0.040404077619314194, -0.038438864052295685, 0.11995998024940491, -0.009761255234479904, -0.048312265425920486, -0.06777894496917725, 0.05436980351805687, 0.15837746858596802, -0.017133202403783798, 0.10998351871967316, -0.07433663308620453, 0.20617249608039856, -0.007218345068395138, -0.07740403711795807, -0.1336568295955658, 0.16840860247612, 0.026932191103696823, 0.006623446941375732, 0.052458036690950394, 0.016645489260554314, 0.2122456133365631, -0.13004028797149658, 0.042762305587530136, 0.10461641848087311, 0.06238093599677086, 0.021750379353761673, -0.039095692336559296, -0.008857257664203644, 0.08566761016845703, 0.023159150034189224, 0.03167152404785156, 0.08704748749732971, -0.014800149016082287, 0.07460781186819077, -0.15425831079483032, -0.01075328141450882, -0.05588734894990921, -0.018651507794857025, -0.09150585532188416, 0.11892946064472198, -0.024899227544665337, -0.08023165911436081, 0.1667940467596054, 0.02335512451827526, 0.011236569844186306, -0.08726619184017181, 0.01628585159778595, -0.07351355999708176, 0.04557126760482788, 0.07051868736743927, 0.005914626177400351, 0.014406591653823853, -0.020134322345256805, 0.11847707629203796, 0.018476424738764763, -0.12199155986309052, 0.04964449256658554, -0.04082236438989639, -0.1457735300064087, -0.08720715343952179, -0.010192562825977802, 0.02424454316496849, -1.0058280963676225e-07, 0.018201328814029694, -0.053074952214956284, -0.05682462826371193, 0.16810211539268494, 0.13331365585327148, -0.04715673252940178, 0.07517167925834656, 0.10547885298728943, 0.12718427181243896, 0.05295640975236893, 0.10402635484933853, 0.026231862604618073, -0.10983867943286896, 0.057327985763549805, -0.029716838151216507, 0.1061738133430481, -0.06574398279190063, -0.08219954371452332, 0.039709653705358505, 0.018349938094615936, 0.0023912619799375534, 0.07478156685829163, 0.018399663269519806, -0.07695899903774261, 0.06443412601947784, -0.017157843336462975, 0.0030040107667446136, 0.016159851104021072, 0.07331247627735138, 0.009960747323930264, -0.07870253175497055, -0.016084594652056694, 0.06342950463294983, -0.060763757675886154, 0.05587278679013252, -0.030158374458551407, -0.0644846111536026, 0.035229094326496124, 0.01117607019841671, 0.1622411608695984, 0.04991866275668144, 0.02500295080244541, -0.04895418882369995, -0.059921592473983765, 0.12311997264623642, -0.04684389382600784, -0.2664334774017334, 0.05513429269194603, 0.0996369794011116, -0.10291463136672974, 0.07421314716339111, 0.00773940933868289, -0.0014982782304286957, 0.0652221217751503, 0.06413619220256805, -0.08546647429466248, -0.046012505888938904, -0.0435551218688488, -0.17323066294193268, 0.10148276388645172, 0.13532958924770355, -0.18806031346321106, -0.03007781319320202, 0.12516604363918304], "changes": {"1wk": 3.9085900106423694}}, {"text": "Cytokinetics Announces 2025 Corporate Milestones and Vision 2030 Cytokinetics, Incorporated Mon, Jan 13, 2025, 3:30 PM 6 min read In This Article: CYTK -2.01% Cytokinetics, Incorporated PDUFA Target Action Date for Aficamten Set for\u00a0September 26, 2025; Commercial Launch Preparations Underway for First Potential Approval Five-Year Aspirations Outline Corporate Strategies to Becoming Leading Muscle Biology Specialty Biopharma Company SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- \u00a0Cytokinetics, Inc. (Nasdaq: CYTK) today provided guidance for corporate milestones expected to occur in 2025 and outlined its aspirational Vision 2030, five-year strategic objectives designed to propel Cytokinetics to becoming the leading muscle-focused specialty biopharmaceutical company intent on meaningfully improving the lives of patients through global access to innovative\u00a0medicines. \u201cIn 2025 we are poised for a defining year with principal focus to the potential approval and commercial launch of aficamten for obstructive HCM in the United States. At the same time, we are executing on a robust clinical trials development program for aficamten inclusive of MAPLE-HCM, with results expected in the first half of this year as may potentially support the use of aficamten as monotherapy,\u201d said Robert I. Blum, Cytokinetics\u2019 President and Chief Executive Officer. \u201cIn addition, we are advancing our later-stage development programs for omecamtiv mecarbil and CK-586 in adjacent specialty cardiology indications with intention to further augment our pipeline over time. Cytokinetics is well positioned to prudently and meaningfully deliver increased shareholder value as we continue to execute well on key milestones and position the company to achieve longer-term aspirations defining of our Vision 2030.\u201d Expected 2025 Milestones Cardiac Muscle Programs Aficamten (cardiac myosin inhibitor) Advance go-to-market strategies and prepare to commercially launch aficamten in the U.S. in 2H 2025, subject to approval by the U.S. Food & Drug Administration (FDA). Continue go-to-market plans in Germany and expand commercial readiness activities in Europe in 2025, in preparation for potential approval by the European Medicines Agency (EMA) in 1H 2026. Coordinate with Sanofi to support the potential approval of aficamten in China in 2H 2025, pending approval by the National Medical Products Administration (NMPA). Report topline results from MAPLE-HCM ( M etoprolol vs A ficamten in P atients with L VOT Obstruction on E xercise Capacity in HCM) , the Phase 3 clinical trial comparing aficamten as monotherapy to metoprolol as monotherapy in patients with symptomatic obstructive HCM, in 1H 2025. Complete patient enrollment of ACACIA-HCM ( A ssessment C omparing A ficamten to Placebo on C ardiac Endpoints I n A dults with Non-Obstructive HCM ), the pivotal Phase 3 clinical trial of aficamten in patients with non-obstructive HCM, in 2H 2025. Complete enrollment of the adolescent cohort in CEDAR-HCM ( C linical E valuation of D osing with A ficamten to R educe Obstruction in a Pediatric Population in HCM ), a clinical trial of aficamten in a pediatric population with symptomatic obstructive HCM, in 2H 2025. Story Continues Omecamtiv mecarbil (cardiac myosin activator) Continue patient enrollment in COMET-HF ( C onfirmation of O mecamtiv M ecarbil E fficacy T rial in H eart F ailure), a confirmatory Phase 3 clinical of omecamtiv mecarbil in patients with symptomatic heart failure with severely reduced ejection fraction (HFrEF) through 2025 to enable completion of enrollment in 2026. CK-586 (cardiac myosin inhibitor) Complete enrollment of the first two patient cohorts in AMBER-HFpEF, ( A ssessment of CK-586 in a M ulti-Center, B linded E valuation of Safety and Tolerability R esults in HFpEF ), a Phase 2 clinical trial of CK-586 in patients with symptomatic heart failure with preserved ejection fraction (HFpEF) in 2H 2025. Skeletal Muscle Program CK-089 (fast skeletal muscle troponin activator) Complete the Phase 1 study of CK-089 in healthy human participants in 2025. Ongoing Research Continue ongoing pre-clinical development and research activities directed to additional muscle biology focused programs. Vision 2030 The Company also outlined its Vision 2030: \u201cEmpowering Muscle, Empowering Lives\u201d with the following objectives: Innovation : Advance two approved products across three indications and ten novel molecular entities (NMEs) in our pipeline. Ignition : Achieve broad access and rapid use of our medicines in >15 countries throughout North America and Europe. Impact : Reach >100,000 patients globally with our medicines. Inspiration : Foster a patient-centric culture with emphasis on equitable access. Ingenuity : Extend our leadership in muscle biology deploying multiple therapeutic modalities. \u201cOur Vision 2030 provides the aspirational roadmap, aligned with our corporate five-year strategic plan, that will propel us forward as a fully integrated and leading specialty biopharma company intent on delivering innovative medicines to patients around the world,\u201d said Mr. Blum. \u201cVision 2030 articulates ambitious company goals to deliver product approvals, achieve broad access to our medicines, promote equitable access and advance our pioneering research to benefit patients, shareholders and employees.\u201d About Cytokinetics Cytokinetics is a late-stage, muscle biology specialty biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, Cytokinetics is intent on meaningfully improving the lives of patients through global access to innovative\u00a0medicines. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a next-in-class cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil , a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function. For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X , LinkedIn , Facebook and YouTube . Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the \u201cAct\u201d). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act\u2019s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements express or implied relating to the properties or potential benefits of aficamten or any of our other drug candidates, our ability to obtain regulatory approval for aficamten for the treatment of obstructive hypertrophic cardiomyopathy or any other indication from FDA or any other regulatory body in the United States or abroad on a timely basis, or at all, the labeling or post-marketing conditions that FDA or another regulatory body may require in connection with the approval of aficamten, our ability to timely enroll and complete the ACACIA-HCM, AMBER-HFpEF, CEDAR-HCM, COMET-HF or CK-089 clinical trials, our ability to timely report the results of the MAPLE-HCM trial, and our ability achieve any element of our Vision 2030. Such statements are based on management\u2019s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics\u2019 business outlines in Cytokinetics\u2019 filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics\u2019 actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. CYTOKINETICS\u00ae and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries. Contact: Cytokinetics Diane Weiser Senior Vice President, Corporate Affairs (415) 290-7757 View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CYTK", "date": "2025-01-13T15:30:00", "sentiment": {"score": 0.87333062896505, "confidence": 0.8807958364486694, "probabilities": {"positive": 0.8807958364486694, "negative": 0.0074652074836194515, "neutral": 0.11173895001411438}}, "embedding": [-0.128730908036232, -0.10494136065244675, 0.06510217487812042, -0.16711583733558655, -0.0680980533361435, -0.05387187749147415, -0.14464648067951202, 0.23798596858978271, 0.03134946897625923, 0.00765308178961277, -0.0843823254108429, 0.01042746938765049, 0.03704400360584259, 0.12917765974998474, 0.013202306814491749, 0.02799198403954506, 0.09787677973508835, 0.05564333125948906, -0.07397876679897308, 0.06343187391757965, 0.004466058686375618, -0.04840777814388275, 0.027846775949001312, 0.11404731869697571, -0.09060177206993103, -0.017764316871762276, -0.1204940602183342, -0.06981496512889862, -0.14668989181518555, 0.02767810970544815, -0.017095286399126053, 0.11680255085229874, 0.11316008865833282, 0.027720823884010315, 0.020381376147270203, 0.025142578408122063, -0.07982628047466278, -0.024276118725538254, -0.11069950461387634, -0.05223088338971138, 0.007833937183022499, -0.11341925710439682, -0.1072225496172905, 0.08573871850967407, 0.15310515463352203, -0.04752914234995842, -0.014022870920598507, 0.009647931903600693, -0.09473592042922974, 0.18812867999076843, -0.14697585999965668, -0.21492131054401398, 0.05575978755950928, 0.01297750510275364, -0.08292987942695618, -0.0033277608454227448, -0.24635529518127441, -0.0753403753042221, 0.05237727612257004, -0.05773714929819107, -0.07227535545825958, -0.08269083499908447, -0.05279044806957245, -0.011263484135270119, -0.005484789609909058, -0.028713461011648178, 0.044248662889003754, 0.05805381387472153, 0.12052657455205917, -0.040196385234594345, 0.0984230637550354, -0.1346149742603302, -0.03109150379896164, 0.13193827867507935, -0.046639833599328995, 0.192854642868042, 0.17216232419013977, 0.13884000480175018, 0.08395296335220337, -0.19824355840682983, 0.13274407386779785, 0.07965933531522751, 0.0616130605340004, 0.0017981715500354767, -0.06414152681827545, 0.07188200205564499, -0.03723568469285965, 0.19685307145118713, -0.02960602380335331, 0.07118632644414902, 0.10580914467573166, 0.027766156941652298, 0.013252566568553448, -0.0009451780933886766, -0.06296218931674957, -0.03771878406405449, -0.033416248857975006, 0.014874020591378212, 0.057192109525203705, -0.0028585027903318405, 0.07105252891778946, 0.06317228078842163, -0.09213464707136154, -0.06691473722457886, -0.054522838443517685, -0.126152902841568, 0.039939336478710175, -0.03577669709920883, 0.1498432159423828, -0.03230374678969383, -0.0006492189131677151, -0.07455267012119293, -0.07583051919937134, -0.1253202110528946, -0.036772146821022034, 0.31434696912765503, -0.02852996252477169, 0.004297914914786816, 0.21934717893600464, 0.009324808605015278, 0.06916988641023636, -0.061396799981594086, -0.0038679447025060654, -0.052166104316711426, -0.05264662206172943, 0.1254054456949234, -0.14141112565994263, 1.0733690913959765e-32, -0.0518040657043457, 0.005724230781197548, 0.10113859176635742, 0.11971046775579453, -0.08157441020011902, -0.06285428255796432, 0.09071986377239227, -0.027596384286880493, -0.09522220492362976, -0.19089925289154053, -0.1281338632106781, 0.03618478402495384, 0.009303577244281769, 0.09429848194122314, -0.06800424307584763, -0.2289513647556305, -0.04509519040584564, 0.00843554176390171, -0.0008941544219851494, 0.03428260236978531, 0.11355555057525635, -0.06089124083518982, -0.08658022433519363, 0.03055413067340851, 0.04088721424341202, 0.11502949893474579, -0.0066890534944832325, 0.04929697513580322, 0.08508875966072083, 0.07694908231496811, -0.11753809452056885, 0.019767513498663902, -0.00513320229947567, -0.10345793515443802, 0.0030457405373454094, -0.07738303393125534, -0.11596973240375519, -0.12873373925685883, 0.03098670020699501, 0.025310680270195007, -0.02920602634549141, 0.02329411171376705, -0.10807924717664719, -0.13476932048797607, 0.18600553274154663, -0.1101362556219101, -0.041526928544044495, 0.0261886864900589, -0.016470788046717644, -0.09376949071884155, 0.1292349100112915, -0.00558167789131403, -0.010302841663360596, -0.07565204799175262, -0.005179509520530701, 0.08581440150737762, -0.15923863649368286, -0.034108586609363556, -0.009183789603412151, 0.026874616742134094, 0.05008593946695328, 0.041016045957803726, -0.05452345684170723, 0.05777781456708908, -0.10727998614311218, 0.1402353048324585, -0.10272283107042313, -0.00962670799344778, -0.15120407938957214, 0.19365841150283813, -0.003149394877254963, -0.09963653981685638, 0.04902813211083412, -0.07556271553039551, 0.18629500269889832, 0.058866437524557114, 0.0481855683028698, 0.18038159608840942, -0.05197599530220032, 0.04883955791592598, -0.026937389746308327, 0.09883993864059448, -0.10786746442317963, 0.1596902310848236, 0.129903644323349, -0.14528469741344452, 0.14820607006549835, -0.04552508890628815, -0.14081910252571106, -0.00922098383307457, 0.10678388178348541, -0.05480086803436279, 0.033754073083400726, 0.28278523683547974, -0.05673541873693466, -1.3648872088276913e-32, 0.011084642261266708, 0.08969816565513611, -0.011821256950497627, -0.129074826836586, -0.030749114230275154, 0.10003812611103058, 0.04532554745674133, -0.1027926579117775, 0.14657598733901978, -0.0541982501745224, 0.05765952914953232, 9.091384708881378e-05, -0.05646897479891777, 0.07519002258777618, -0.1824958473443985, 0.02451356127858162, -0.04180010035634041, -0.036968398839235306, -0.1929110884666443, 0.1190357357263565, 0.06290106475353241, 0.044321127235889435, -0.0501222088932991, 0.12033817917108536, 0.11293812096118927, 0.06562576442956924, 0.07651890814304352, 0.03997058793902397, 0.1345193088054657, -0.09135664999485016, -0.07703635841608047, -0.0364973247051239, -0.18150106072425842, -0.0443926565349102, 0.01916465163230896, 0.01812356524169445, 0.015113684348762035, -0.10884016007184982, 0.03784532472491264, -0.05799204483628273, -0.010637791827321053, -0.10347156971693039, -0.04567733779549599, 0.08488737791776657, -0.010392716154456139, -0.0231044739484787, 0.15358856320381165, -0.04178202897310257, 0.07305993139743805, 0.030742332339286804, -0.06091039627790451, 0.03899344056844711, -0.010864629410207272, 0.09931748360395432, -0.10046204924583435, 0.01849573850631714, 0.11293604224920273, 0.053506262600421906, -0.04786865785717964, -0.05694158002734184, -0.0032097590155899525, 0.03288101777434349, 0.10840936750173569, -0.024990705773234367, 0.10811656713485718, 0.04997492954134941, 0.13232046365737915, 0.0951998382806778, -0.04068755358457565, -0.09109941124916077, -0.008659664541482925, 0.018513454124331474, -0.13575243949890137, -0.03901677951216698, 0.033407486975193024, 0.013313096016645432, 0.07940967381000519, -0.23585376143455505, -0.1741771250963211, -0.04856887832283974, -0.001965045928955078, -0.03660466521978378, -0.029750412330031395, 0.027547724545001984, 0.058892954140901566, -0.020483558997511864, 0.14625191688537598, 0.03100287914276123, -0.0341682955622673, 0.05367475375533104, -0.06899502128362656, -0.06949566304683685, -0.06482242047786713, 0.2087143212556839, 0.033899445086717606, -1.0120189841700267e-07, 0.10082893818616867, 0.010280839167535305, -0.10575795918703079, -0.05984994396567345, -0.03851889818906784, -0.08523782342672348, -0.15793603658676147, -0.03367684781551361, -0.016695760190486908, 0.08630351722240448, 0.06586238741874695, 0.184513121843338, -0.03922930732369423, -0.07040975987911224, -0.012330524623394012, -0.00814816728234291, -0.09103019535541534, 0.012066470459103584, -0.04713936895132065, 0.008935876190662384, -0.13379234075546265, 0.003031384199857712, 0.02067599445581436, -0.07736817747354507, -0.023614972829818726, -0.23338112235069275, -0.024028757587075233, 0.1526753306388855, 0.07571396231651306, -0.07066553086042404, 0.055599287152290344, 0.016717664897441864, 0.01713123358786106, 0.04513804614543915, -0.1246735155582428, -0.12953677773475647, -0.06917756795883179, 0.03832218796014786, 0.03674344718456268, 0.07941562682390213, -0.031398311257362366, -0.029178764671087265, 0.0005073817446827888, 0.04474819451570511, -0.037006836384534836, -0.18093359470367432, -0.030469004064798355, -0.06782408058643341, 0.005521952174603939, -0.007055722177028656, -0.10740835964679718, 0.01891055330634117, 0.004697468131780624, -0.06548367440700531, 0.036825135350227356, 0.15119442343711853, -0.08844016492366791, -0.12605226039886475, 0.011504187248647213, -0.042354434728622437, 0.001245100051164627, -0.15587064623832703, 0.12461084127426147, 0.051203642040491104], "changes": {"1wk": -2.076637604406004}}, {"text": "Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference Cytokinetics, Incorporated Tue, Jan 7, 2025, 12:00 AM 3 min read In This Article: CYTK -2.01% Cytokinetics, Incorporated SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:00 AM Pacific Time in the Borgia Room of the Westin St. Francis Hotel in San Francisco, CA. Interested parties may access the live webcast of the presentation by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com . The webcast replay will be archived on the Cytokinetics website for 90 days following the conclusion of the event. About Cytokinetics Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Cytokinetics is readying for the potential commercialization of aficamten, a next-in-class cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil , a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function. For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X , LinkedIn , Facebook and YouTube . Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the \"Act\"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics\u2019 product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Story Continues CYTOKINETICS\u00ae and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries. Contact: Cytokinetics Diane Weiser Senior Vice President, Corporate Affairs (415) 290-7757 View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CYTK", "date": "2025-01-07T00:00:00", "sentiment": {"score": 0.13280820474028587, "confidence": 0.1422482430934906, "probabilities": {"positive": 0.1422482430934906, "negative": 0.009440038353204727, "neutral": 0.8483117818832397}}, "embedding": [-0.08657943457365036, -0.10698840767145157, 0.025325609371066093, -0.10661709308624268, -0.020341886207461357, -0.05062178149819374, -0.07887531816959381, 0.22719714045524597, 0.03676415607333183, -0.0042243232019245625, -0.06253302097320557, 0.005775736644864082, 0.10918991267681122, 0.13054658472537994, 0.03853578865528107, 0.033101700246334076, 0.12805676460266113, 0.25659051537513733, -0.10755898058414459, 0.15483519434928894, 0.032924581319093704, 0.06710359454154968, -0.022674724459648132, 0.19126957654953003, -0.12007385492324829, -0.025795578956604004, -0.1009175032377243, 0.014938280917704105, -0.21608498692512512, 0.029110796749591827, -0.14342409372329712, 0.039435386657714844, 0.19269204139709473, 0.10904915630817413, 0.04076331481337547, 0.12663421034812927, -0.0739428699016571, -0.07869520783424377, -0.052586767822504044, -0.0598498210310936, -0.0015499163419008255, -0.07310032099485397, -0.030448684468865395, 0.02615954540669918, 0.20040680468082428, 0.006026014685630798, -0.009425899013876915, 0.010832206346094608, -0.0685940608382225, 0.19428130984306335, -0.20158526301383972, -0.013105101883411407, 0.056026630103588104, 0.06291666626930237, -0.04750873148441315, -0.003505113534629345, -0.2933145761489868, -0.020512808114290237, -0.0403565913438797, -0.07824932038784027, -0.019039805978536606, -0.019152488559484482, 0.018997542560100555, -0.011556878685951233, 0.004934235941618681, 0.006354759447276592, 0.01574324257671833, 0.11948144435882568, 0.11896152794361115, -0.01811128854751587, 0.10304185748100281, -0.11744613945484161, -0.045908086001873016, 0.14016465842723846, -0.036952193826436996, 0.15339581668376923, 0.12517747282981873, 0.05842910334467888, -0.00038742460310459137, -0.16123345494270325, 0.12044674903154373, 0.015250052325427532, 0.1293884962797165, 0.012960807420313358, -0.03339141234755516, 0.0783655047416687, -0.03445323929190636, 0.12824629247188568, -0.014223238453269005, 0.1323733925819397, 0.118567556142807, 0.11927752196788788, 0.057443030178546906, -0.017333243042230606, 0.03326372802257538, -0.08689133822917938, -0.02768862061202526, 0.08338800072669983, 0.087563157081604, -0.01839904859662056, 0.13510450720787048, 0.04935096204280853, -0.08594062179327011, -0.07748489081859589, 0.09636056423187256, -0.07513564825057983, 0.0746125653386116, -0.027915632352232933, 0.1681339591741562, 0.05856635794043541, 0.013551559299230576, -0.05828127637505531, -0.11674432456493378, -0.11893819272518158, 0.05591452866792679, 0.36842578649520874, 0.012127574533224106, 0.040432073175907135, 0.11785511672496796, 0.05753779038786888, 0.09607402980327606, -0.16506825387477875, -0.009663267061114311, -0.0904478207230568, -0.13396957516670227, 0.15199658274650574, -0.19817142188549042, 9.556946865705759e-33, 0.003503597341477871, -0.06265824288129807, 0.14458522200584412, 0.05335812643170357, 0.06805042177438736, -0.13625696301460266, 0.010945343412458897, -0.07190011441707611, -0.11444798111915588, -0.20676368474960327, -0.15438425540924072, -0.002157849259674549, 0.11950954794883728, 0.02606559358537197, -0.14175060391426086, -0.13491597771644592, -0.13026684522628784, -0.026498842984437943, 0.04865943640470505, -0.023915842175483704, 0.11446089297533035, 0.0022986531257629395, -0.06128470599651337, 0.012625454925000668, -0.0498742014169693, 0.099399134516716, 0.013255869969725609, 0.0859595537185669, 0.03494521975517273, 0.0020234007388353348, -0.15074077248573303, -0.051445167511701584, -0.021707424893975258, -0.12188407778739929, 0.040137000381946564, -0.17282435297966003, -0.11548306047916412, -0.10913023352622986, 0.012096108868718147, -0.01300223171710968, -0.1589992642402649, -0.06267398595809937, -0.11473612487316132, -0.13604439795017242, 0.18024471402168274, -0.11646153032779694, 0.01680147275328636, -0.0227399542927742, -0.06896723806858063, -0.01088122557848692, 0.16278760135173798, -0.04353754222393036, 0.05910339206457138, -0.11453642696142197, -0.019592532888054848, -0.006556835025548935, -0.1091582179069519, 0.05456789582967758, -0.02915768139064312, 0.07179000973701477, 0.03726762533187866, 0.023311862722039223, -0.00231922697275877, 0.09003086388111115, -0.11906400322914124, 0.08481787890195847, -0.1946241706609726, -0.04774422571063042, -0.1654393970966339, 0.10546202957630157, 0.07959520071744919, -0.1173446774482727, 0.04450967162847519, -0.062025971710681915, 0.16361738741397858, 0.0066818539053201675, -0.005408463533967733, 0.18917909264564514, -0.1784004271030426, -0.07691140472888947, -0.037399303168058395, 0.049313340336084366, -0.10294994711875916, 0.16727763414382935, 0.001433705911040306, -0.08910903334617615, 0.20103028416633606, -0.086988165974617, -0.07399000227451324, -0.04821097478270531, 0.11979325115680695, -0.13077464699745178, -0.014018449001014233, 0.2024204134941101, -0.09534353017807007, -1.0517726887774786e-32, -0.042667437344789505, 0.05326437950134277, 0.06048623472452164, -0.08859594166278839, -0.07275956869125366, 0.14989441633224487, 0.06926009058952332, -0.1654263436794281, 0.17031648755073547, -0.12028314918279648, 0.06516747921705246, -0.047393444925546646, -0.06123344600200653, 0.061342302709817886, -0.16667301952838898, 0.12216228991746902, -0.09275422990322113, -0.09103058278560638, -0.23476079106330872, 0.1912657916545868, 0.0903407633304596, 0.05079563707113266, -0.012942848727107048, 0.1409679651260376, 0.07154655456542969, 0.096180260181427, 0.062309473752975464, 0.10093961656093597, 0.1488371193408966, -0.0802193209528923, 0.003846392035484314, 0.001182757318019867, -0.23077011108398438, -0.06156087666749954, 0.02931424230337143, 0.060377608984708786, -0.07327646017074585, -0.0031955093145370483, 0.038666244596242905, -0.10594595968723297, 0.010957298800349236, -0.0781618058681488, 0.02605881169438362, 0.07033482193946838, -0.015107207000255585, 0.021480794996023178, 0.16109566390514374, -0.07258477807044983, -0.07558857649564743, 0.11890259385108948, -0.03835195302963257, -0.009012898430228233, 0.03438377007842064, 0.09473150223493576, -0.012355961836874485, 0.05786653235554695, 0.08004899322986603, 0.1197083368897438, -0.08053626120090485, -0.0029090335592627525, -0.05436769872903824, -0.04955391585826874, 0.10288587957620621, -0.008418399840593338, 0.17628547549247742, 0.05845801159739494, 0.11558350920677185, 0.1239205151796341, 0.0256954338401556, -0.017179859802126884, 0.03425319865345955, 0.11618877947330475, 0.02645132690668106, 0.06646601110696793, 0.014064114540815353, 0.062221698462963104, 0.040778301656246185, -0.14152315258979797, -0.23253923654556274, -0.06126857548952103, 0.08121232688426971, -0.1142839789390564, -0.03611200302839279, -0.04599948227405548, -0.04050346463918686, 0.008006769232451916, 0.21114814281463623, 0.10369819402694702, -0.013984763994812965, 0.04198587313294411, 0.03248114138841629, -0.030620073899626732, -0.05076383426785469, 0.1611410528421402, -0.005232257768511772, -9.999466499266418e-08, 0.07856935262680054, -0.09557776153087616, -0.12492014467716217, -0.20853106677532196, -0.08191095292568207, -0.07250092178583145, -0.03452378138899803, -0.06796318292617798, -0.06170966476202011, 0.039092227816581726, 0.10165351629257202, 0.10028624534606934, 0.041433386504650116, -0.17005760967731476, -0.05129638686776161, -0.08634322136640549, -0.13890299201011658, -0.04222332686185837, -0.029293451458215714, 0.03198104351758957, -0.0820162296295166, -0.05333467572927475, -0.06352119892835617, -0.037665076553821564, 0.1236686259508133, -0.1793391853570938, 0.0015881825238466263, 0.1151602566242218, 0.07701969146728516, -0.13381236791610718, -0.003180504310876131, 0.008381262421607971, 0.06574610620737076, 0.0712742805480957, -0.10512292385101318, -0.09935362637042999, -0.04895897954702377, -0.02086494117975235, -0.08685079216957092, 0.08999265730381012, -0.07212384790182114, -0.10225291550159454, -0.0037345802411437035, -0.006330914795398712, 0.006551288068294525, -0.11422917246818542, -0.001058223657310009, 0.010555248707532883, 0.13725706934928894, -0.0211816243827343, -0.09148497879505157, 0.015574870631098747, 0.019083496183156967, -0.11362873017787933, -0.032943058758974075, 0.15002694725990295, -0.10996827483177185, 0.026197906583547592, 0.05749556049704552, -0.05561260133981705, -0.03803417831659317, -0.0745106190443039, 0.04202387109398842, 0.02236582338809967], "changes": {"1wk": -5.041674347373834}}, {"text": "PREMIUM Cytokinetics Says European Regulator Validated its Application for Cardiomyopathy Drug Candidate MT Newswires Mon, Dec 23, 2024, 4:03 PM 1 min read In This Article: CYTK -2.01% Cytokinetics (CYTK) said Monday that the European Medicines Agency has validated its marketing autho PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CYTK", "date": "2024-12-23T16:03:56", "sentiment": {"score": 0.07207620982080698, "confidence": 0.08330146968364716, "probabilities": {"positive": 0.08330146968364716, "negative": 0.011225259862840176, "neutral": 0.9054732918739319}}, "embedding": [-0.14160284399986267, -0.005521279759705067, -0.04276091977953911, -0.016431085765361786, 0.18518874049186707, -0.017673462629318237, -0.052547723054885864, 0.19615495204925537, -0.0013674485962837934, -0.08471907675266266, 0.0012642067158594728, 0.09153095632791519, 0.12557433545589447, 0.11630867421627045, -0.03755127266049385, -0.05454152449965477, 0.11749642342329025, 0.07906989008188248, -0.05000627413392067, 0.09044093638658524, -0.1460510641336441, -0.03024004027247429, 0.05380845069885254, 0.13811933994293213, -0.029507717117667198, -0.05246393755078316, -0.1499483734369278, -0.037086453288793564, 0.002222108654677868, 0.11040910333395004, -0.07627271115779877, 0.016392860561609268, 0.15753430128097534, -0.02170460671186447, 0.05742846056818962, -0.03672558814287186, -0.04930845648050308, -0.04164210334420204, -0.2242402285337448, 0.04318463057279587, 0.1449296921491623, -0.23513564467430115, -0.11950386315584183, 0.15048952400684357, 0.15221811830997467, 0.0367034450173378, -0.050028134137392044, 0.04266690835356712, -0.19587577879428864, 0.17466208338737488, -0.05640874058008194, -0.14426879584789276, 0.09705818444490433, -0.059245966374874115, -0.052577514201402664, -0.03378178924322128, -0.37220850586891174, -0.06535717099905014, 0.03837331756949425, -0.11284767091274261, -0.025027602910995483, 0.011415950953960419, -0.16091227531433105, 0.13749726116657257, -0.046556003391742706, 0.04098821431398392, -0.1083642989397049, 0.06606122106313705, 0.06831547617912292, -0.16943708062171936, 0.020542647689580917, -0.1726357489824295, 0.030468281358480453, 0.1450386941432953, 0.027962159365415573, 0.2988295555114746, 0.016387609764933586, -0.03310807794332504, 0.04281139373779297, -0.19348253309726715, 0.1042722761631012, -0.006131979636847973, 0.0836372822523117, 0.003852525260299444, 0.09819648414850235, 0.02156679704785347, -0.03370529040694237, 0.07215666025876999, -0.12638172507286072, 0.03702312335371971, 0.3094111382961273, 0.07439889758825302, 0.07272673398256302, 0.047000255435705185, -0.19064286351203918, -0.09778620302677155, -0.10086318105459213, 0.027735186740756035, -0.13115918636322021, 0.08676820248365402, -0.018328629434108734, 0.09532549232244492, -0.09322498738765717, -0.029275652021169662, 0.04808482900261879, -0.15213806927204132, 0.06026767939329147, 0.025646250694990158, 0.10600614547729492, 0.11725766211748123, 0.021984746679663658, -0.046218544244766235, -0.0554211400449276, -0.2670052647590637, -0.03259545937180519, 0.2783436179161072, -0.1589449942111969, -0.010064058937132359, 0.1684620976448059, 0.08829560875892639, 0.030737552791833878, -0.1236053854227066, -0.02741614729166031, -0.08399958908557892, 0.038404710590839386, 0.15167571604251862, -0.13026054203510284, 1.2483341521445783e-32, -0.15230707824230194, 0.09861645102500916, 0.18186238408088684, -0.07118089497089386, -0.027647152543067932, 0.013599858619272709, 0.013135983608663082, -0.22924798727035522, -0.0578136071562767, -0.18403853476047516, -0.1978863775730133, 0.18551665544509888, 0.02785511501133442, 0.07083094865083694, -0.2048082798719406, -0.08348052203655243, -0.10557714849710464, 0.025132687762379646, 0.09144946187734604, 0.1357419490814209, 0.22938527166843414, -0.12257644534111023, -0.009597712196409702, -0.02181597426533699, -0.11275756359100342, 0.11594100296497345, 0.08656349778175354, 0.02513047866523266, 0.21469265222549438, 0.11511557549238205, -0.19769755005836487, -0.017678266391158104, 0.047235485166311264, -0.0714949518442154, -0.0595029816031456, 0.07480509579181671, 0.015507138334214687, -0.1789371520280838, -0.011340347118675709, -0.0925922691822052, -0.0560150183737278, -0.142188161611557, -0.09315823763608932, -0.04316999763250351, 0.11150775104761124, -0.050999242812395096, -0.14341683685779572, -0.07357286661863327, -0.032258041203022, -0.10169099271297455, 0.04930712655186653, -0.010070220567286015, -0.14954155683517456, -0.002124504651874304, -0.03368744999170303, 0.06630817800760269, -0.1378902792930603, 0.04697990417480469, 0.07980333268642426, -0.14549227058887482, 0.1350172758102417, 0.02580632083117962, -0.008171451278030872, -0.0682719275355339, -0.04230593889951706, 0.08862759917974472, -0.1869114488363266, -0.21861831843852997, -0.3106093406677246, 0.124623142182827, 0.16021588444709778, -0.01325590256601572, 0.022883251309394836, 0.0461110919713974, -0.052908364683389664, 0.01153695397078991, -0.004149483982473612, 0.20586392283439636, 0.04242348298430443, 0.06248483806848526, -0.08265898376703262, -0.04411155730485916, 0.029425477609038353, 0.16536957025527954, 0.09383128583431244, -0.034218791872262955, 0.07627396285533905, 0.03952695429325104, -0.04463625326752663, 0.023239655420184135, 0.02975289896130562, 0.015999294817447662, -0.004956592805683613, 0.2514350712299347, -0.09217372536659241, -1.4353880702654334e-32, -0.06287669390439987, 0.10269603133201599, 0.06499097496271133, -0.06235208734869957, -0.06667131185531616, 0.060937944799661636, -0.19154949486255646, 0.07271437346935272, 0.34132257103919983, 0.06690841168165207, 0.15551099181175232, -0.02784554660320282, -0.059913717210292816, 0.08506405353546143, -0.010588320903480053, 0.005661776755005121, -0.05320417508482933, 0.018526863306760788, -0.12559910118579865, 0.12407918274402618, -0.050539035350084305, 0.012063257396221161, -0.09056942164897919, 0.2841697633266449, 0.08991845697164536, -0.03147666156291962, 0.09431971609592438, 0.15847048163414001, -0.0726756751537323, -0.14250637590885162, -0.07595306634902954, 0.0581451952457428, -0.2184285968542099, -0.002541458001360297, -0.02004755660891533, 0.023994768038392067, 0.03989814594388008, 0.07889270037412643, 0.03549695014953613, 0.02168477512896061, -0.06689190119504929, -0.16705119609832764, -0.10624361038208008, 0.0033840241376310587, 0.08263175189495087, 0.02418280579149723, 0.21862773597240448, -0.12855759263038635, 0.17334800958633423, -0.09127184003591537, 0.06712442636489868, -0.010583550669252872, 0.14798055589199066, 0.1619291752576828, -0.10215987265110016, 0.1216735690832138, 0.11152228713035583, 0.09995537996292114, 0.021392853930592537, -0.10148608684539795, 0.07224853336811066, 0.07149845361709595, -0.06381922215223312, -0.0790041908621788, 0.1262563169002533, 0.05414601415395737, 0.1377178132534027, 0.005996453110128641, 0.045296844094991684, 0.03399088606238365, -0.02671842835843563, 0.005458290688693523, -0.175844207406044, 0.003506995039060712, -0.026542089879512787, 0.07135577499866486, 0.0017565195448696613, -0.0759255662560463, -0.14370791614055634, -0.1632085144519806, 0.0818345919251442, -0.10743512958288193, 0.013072393834590912, -0.04132888466119766, -0.05812576785683632, -0.1546965390443802, 0.19273684918880463, -0.06797388195991516, -0.07218372821807861, 0.0676831528544426, -0.0981689915060997, -0.06750641763210297, -0.1932869404554367, 0.12589742243289948, 0.020818328484892845, -1.0054571220052821e-07, 0.06097275763750076, -0.0598452053964138, -0.12417756766080856, 0.028727030381560326, 0.015469463542103767, -0.03296591341495514, -0.09512998163700104, -0.018168898299336433, -0.03583696484565735, 0.045121096074581146, 0.0239099208265543, 0.06508393585681915, -0.02221975475549698, -0.14999598264694214, 0.04503873363137245, 0.019781554117798805, -0.009352627210319042, 0.0903090164065361, 0.012289818376302719, 0.06517859548330307, 0.06720136106014252, 0.10665267705917358, 0.20103423297405243, -0.13582439720630646, -0.04131640866398811, -0.09260036796331406, 0.05839906632900238, 0.0707549899816513, 0.04491686448454857, -0.18375755846500397, 0.04069415479898453, 0.011540329083800316, 0.016167014837265015, 0.07109497487545013, -0.09972939640283585, 0.053333647549152374, -0.022564159706234932, -0.01978977769613266, 0.04972924664616585, -0.008381806313991547, -0.08084431290626526, -0.11182434111833572, 0.007132155820727348, -0.009371195919811726, -0.12173492461442947, -0.10383768379688263, -0.03487250208854675, -0.12208137661218643, 0.09983958303928375, -0.06938470155000687, 0.040971286594867706, 0.009240836836397648, 0.1122937873005867, -0.17711102962493896, -0.01229611411690712, -0.0010753176175057888, -0.050655268132686615, -0.029560500755906105, -0.011895807459950447, -0.05931204557418823, -0.010621990077197552, -0.14619316160678864, 0.18413181602954865, 0.04104845970869064], "changes": {"1wk": -3.248212722790591, "1mo": -6.39428195981764}}, {"text": "Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Cytokinetics, Incorporated Sat, Jan 4, 2025, 12:00 AM 5 min read In This Article: CYTK -2.01% Cytokinetics, Incorporated SOUTH SAN FRANCISCO, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 31, 2024 it granted stock options to purchase an aggregate of 52,188 shares of common stock, 33,885 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting\u00a0and 3,189 performance stock units (PSUs) that, if earned, will be settled in shares of common stock upon vesting to 9 employees, whose employment commenced in December 2024, as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of the RSUs vesting on the second anniversary of the grant date and the final 20% vesting on the third anniversary of the grant date, in each case, subject to each respective employee\u2019s continued service with the Company. The stock options that were granted are subject to an exercise price of $47.04 per share, which is equal to the closing price of the Company\u2019s common stock on December 31, 2024, and will vest over 4 years, with 1/4 th of the shares underlying the employee\u2019s option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting in monthly installments at a rate of 1/48th of the shares underlying such stock options over the subsequent 36 months, subject to each respective employee\u2019s continued service with the Company. The stock options have a 10-year term. The PSU\u00a0award is subject to two performance goals and will be earned as to up to 50% of the number of shares subject to the PSU award upon the certification by Compensation and Talent Committee of the Company\u2019s Board of Directors (Committee) that the Company has achieved the first performance goal and as to up to 50% of the number of shares subject to the PSU award upon the certification by the Committee that the Company has achieved the second performance goal. The earned shares will vest as to 50% of the earned shares on applicable Committee certification date and as to 50% of the earned shares following the\u00a0one-year\u00a0anniversary of the applicable Committee certification date, subject to the respective employee\u2019s continued service with the Company. These awards are subject to the terms and conditions of the Company's Amended and Restated 2004 Equity Incentive Plan and the applicable award agreements pursuant to which the awards were granted. The stock options, RSUs and PSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4). Story Continues About Cytokinetics Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Cytokinetics is readying for the potential commercialization of aficamten, a next-in-class cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil , a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function. For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X , LinkedIn , Facebook and YouTube . Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the \"Act\").\u00a0Cytokinetics\u00a0disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's\u00a0Safe Harbor\u00a0for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to\u00a0Cytokinetics'\u00a0and its partners' research and development activities of Cytokinetics\u2019 product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to\u00a0Cytokinetics'\u00a0business outlined in\u00a0Cytokinetics'\u00a0filings with the\u00a0Securities and Exchange Commission particularly under the caption \u201cRisk Factors\u201d in Cytokinetics\u2019 latest Annual Report on Form 10-K. Forward-looking statements are not guarantees of future performance, and\u00a0Cytokinetics'\u00a0actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that\u00a0Cytokinetics\u00a0makes in this press release speak only as of the date of this press release.\u00a0Cytokinetics\u00a0assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. CYTOKINETICS\u00ae and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries. Contact: Cytokinetics Diane Weiser Senior Vice President, Corporate Affairs (415) 290-7757 View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CYTK", "date": "2025-01-04T00:00:00", "sentiment": {"score": 0.01921086013317108, "confidence": 0.03447098657488823, "probabilities": {"positive": 0.03447098657488823, "negative": 0.015260126441717148, "neutral": 0.9502689242362976}}, "embedding": [-0.12222270667552948, 0.007966144010424614, 0.03196953982114792, -0.055299267172813416, -0.16286781430244446, 0.15490736067295074, 0.028062716126441956, 0.1184196025133133, 0.03923971578478813, -0.001956904772669077, 0.04475267231464386, 0.07306624948978424, 0.09524883329868317, 0.013257231563329697, -0.012782932259142399, 0.016979752108454704, -0.011441757902503014, 0.0508924201130867, -0.14351189136505127, -0.016926776617765427, -0.03434403985738754, -0.18820026516914368, -0.14136475324630737, -0.10810504853725433, 0.14054885506629944, -0.028739523142576218, -0.04290125146508217, 0.10217133164405823, -0.024428073316812515, 0.06105658411979675, -0.00904542300850153, 0.08727231621742249, 0.07960398495197296, -0.03389407694339752, -0.08194851875305176, -0.022143732756376266, -0.09623421728610992, 0.073598712682724, 0.09023047238588333, -0.005468924529850483, 0.007077494636178017, 0.009649712592363358, -0.08468402922153473, 0.019922897219657898, 0.004153059329837561, 0.03433326259255409, -0.0010867493692785501, 0.017585746943950653, -0.0668107122182846, -0.035746462643146515, -0.02709253877401352, 0.000640717800706625, 0.04147389903664589, 0.10577833652496338, -0.15137910842895508, -0.04018530994653702, -0.19192065298557281, -0.02516404539346695, 0.05802407115697861, -0.028405722230672836, -0.0359356552362442, -0.04731599986553192, -0.08915701508522034, 0.0461614653468132, 0.16154111921787262, -0.020797060802578926, -0.008564298041164875, 0.044012539088726044, 0.01858808845281601, 0.015225626528263092, 0.1002463847398758, -0.016428660601377487, -0.19444304704666138, -0.04894427955150604, -0.13970546424388885, 0.2970099449157715, 0.07602006942033768, 0.05999094247817993, -0.00944984145462513, -0.2815873324871063, -0.012091685086488724, 0.05871571600437164, 0.011224945075809956, -0.0821981281042099, -0.022780083119869232, -0.0069242240861058235, 0.04543176293373108, 0.13846325874328613, 0.09743324667215347, 0.014347466640174389, 0.09524337202310562, -0.01866181194782257, -0.02614213526248932, -0.10342864692211151, -0.0027486011385917664, -0.026595033705234528, -0.09202395379543304, -0.03924410045146942, 0.0026404932141304016, 0.08440906554460526, 0.0677458643913269, 0.05365346744656563, -0.1133471354842186, -0.07509028911590576, -0.06036321818828583, -0.004410584457218647, -0.03146032989025116, -0.06542687118053436, 0.0036696214228868484, 0.0003383453004062176, -0.15903538465499878, 0.006245651748031378, -0.15113690495491028, -0.0714818611741066, -0.1716253161430359, 0.1810826063156128, 0.02021998167037964, 0.0730334222316742, 0.14515841007232666, -0.0846705436706543, 0.08825697004795074, 0.022778581827878952, -0.05676115304231644, -0.0372452512383461, -0.09171996265649796, -0.08265401422977448, -0.16846834123134613, 1.1767697621929297e-32, -0.11045338958501816, -0.06898786127567291, 0.06251603364944458, -0.032000716775655746, -0.006785827223211527, -0.05337638780474663, 0.05732099711894989, -0.04581504315137863, -0.07652713358402252, 0.10475510358810425, -0.1553015112876892, 0.1487588882446289, 0.0823325365781784, -0.10391920804977417, 0.04115958511829376, -0.09395771473646164, -0.017516203224658966, 0.10234782099723816, 0.10529471933841705, -0.018370451405644417, 0.10066075623035431, 0.04944846034049988, -0.04098723456263542, 0.06732650101184845, 0.14634406566619873, -0.06398816406726837, 0.013129806146025658, -0.05494701862335205, -0.07351547479629517, 0.042821336537599564, 0.048154789954423904, 0.05637133866548538, -0.08645618706941605, -0.028162265196442604, 0.03374280408024788, -0.01145850121974945, 0.018327433615922928, -0.0689440369606018, 0.0653921440243721, -0.0617687851190567, -0.05433952435851097, -0.028751149773597717, 0.021807847544550896, -0.09028686583042145, -0.08487599343061447, 0.02648857980966568, -0.01881411485373974, 0.024989526718854904, 0.06766830384731293, 0.1275779753923416, -0.016244813799858093, 0.05587814375758171, -0.05140703544020653, -0.09536823630332947, 0.0074602290987968445, -0.05564842000603676, -0.09410808980464935, 0.033854059875011444, 0.07702646404504776, 0.10052712261676788, 0.057636458426713943, 0.08414899557828903, -0.07388794422149658, 0.06925737857818604, -0.1452769637107849, 0.15956701338291168, -0.13187935948371887, -0.13330765068531036, 0.03931337222456932, 0.0634111613035202, -0.03826465457677841, 0.04361511766910553, 0.11015207320451736, -0.12395096570253372, 0.07658647745847702, -0.10855066031217575, 0.06655994057655334, 0.060808487236499786, 0.04220189154148102, 0.06959210336208344, -0.06293578445911407, -0.05057358741760254, -0.10753272473812103, 0.030257482081651688, 0.13222673535346985, -0.01138791348785162, 0.09092570096254349, 0.028950970619916916, -0.11048927158117294, -0.03509025648236275, 0.125358447432518, -0.07629003375768661, 0.05180623382329941, 0.24715018272399902, -0.004599431529641151, -1.0740076052336638e-32, -0.1274040937423706, 0.020408976823091507, -0.015360267832875252, -0.011395237408578396, 0.08199198544025421, 0.06941652297973633, 0.049663517624139786, -0.017583826556801796, -0.10296183079481125, 0.041779775172472, -0.04152798652648926, 0.04460067301988602, 0.019826024770736694, 0.07877057045698166, -0.19850361347198486, 0.036557551473379135, 0.034032564610242844, 0.06806734204292297, -0.030748773366212845, 0.06342080980539322, 0.0289897583425045, 0.20282244682312012, 0.06213601678609848, 0.21695441007614136, 0.11811605840921402, 0.07594320178031921, 0.08913002163171768, 0.09841671586036682, 0.012950185686349869, 0.015215297229588032, -0.05032791942358017, -0.07888942956924438, -0.25907841324806213, 0.04339294880628586, 0.005811702460050583, -0.20160797238349915, 0.14685143530368805, -0.057275183498859406, 0.10668106377124786, 0.07569112628698349, 0.03024407848715782, -0.07006212323904037, 0.08079639077186584, 0.17869582772254944, 0.07747498154640198, -0.07481841742992401, 0.14550387859344482, -0.12368530035018921, 0.10292954742908478, 0.0006626695394515991, 0.04133804515004158, 0.0008601495064795017, 0.009496672078967094, 0.18032190203666687, 0.04034877195954323, 0.05637732893228531, 0.046148065477609634, -0.03299668803811073, -0.013749110512435436, -0.028909940272569656, 0.15428426861763, 0.029848378151655197, 0.0007787663489580154, 0.011324310675263405, 0.09927209466695786, -0.05584309250116348, -0.0035726577043533325, -0.013290071859955788, -0.07279501110315323, -0.006784010678529739, -0.04248042404651642, -0.17763984203338623, 0.05125359445810318, -0.16036421060562134, 0.060857921838760376, 0.09139616787433624, 0.1548459231853485, -0.15722529590129852, -0.04142876714468002, 0.028679504990577698, -0.19852590560913086, 0.0020882543176412582, -0.007991623133420944, 0.10537784546613693, -0.016402289271354675, -0.007030827924609184, 0.07951051741838455, 0.06389380991458893, 0.07984231412410736, -0.005720516666769981, -0.04490111395716667, -0.05531134083867073, 0.12083663046360016, 0.11294275522232056, -0.04567525163292885, -9.992918847956389e-08, 0.03474137559533119, -0.09917938709259033, -0.07946066558361053, -0.03560175001621246, 0.12907534837722778, -0.0657137930393219, 0.005987181328237057, -0.0748022049665451, -0.01368629653006792, 0.02561219222843647, 0.15326866507530212, 0.06075998395681381, -0.12485760450363159, -0.03638938441872597, -0.0843711644411087, -0.05633042752742767, -0.09225153923034668, 0.06575397402048111, -0.08007009327411652, -0.08431479334831238, 0.006596918683499098, -0.03132558614015579, 0.029392817988991737, 0.0028499793261289597, -0.07633465528488159, -0.011488418094813824, 0.04064801707863808, 0.07913584262132645, 0.031055735424160957, 0.08945111930370331, 0.014940014109015465, -0.031094824895262718, 0.02147551253437996, -0.0624319463968277, -0.11930373311042786, -0.048163700848817825, 0.04391128569841385, 0.09139544516801834, 0.05994340032339096, 0.07354175299406052, -0.048471979796886444, -0.08851895481348038, 0.019148940220475197, 0.11109806597232819, 0.049979180097579956, -0.018114831298589706, -0.2856207489967346, -0.07042275369167328, -0.02411852590739727, -0.1802140176296234, 0.06417199969291687, -0.016908835619688034, -0.03792146220803261, 0.07175508141517639, 0.0711296871304512, 0.048004575073719025, -0.053646087646484375, -0.039634376764297485, -0.035834554582834244, -0.058809299021959305, -0.05992893874645233, -0.09769530594348907, -0.07551007717847824, 0.07199249416589737], "changes": {"1wk": -5.55105681642187, "1mo": 0.2025900990368353}}]